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CHAPTER 1. INTRODUCTION 
  Zwitterionic polymers possess a positively charged group and a negatively charged 
group in each repeating unit1. The specific poly-salt-like structure rendered 
zwitterionic polymer a super-hydrophilic nature2-3. These years, intense studies have 
been focused on the unique properties and potential applications of zwitterionic 
polymers in biomedical fields such as drug delivery4-5, implantable devices6-7, and 
tissue engineering8-9.  
  Common zwitterionic materials include poly-phosphobetaine (PPC), 
poly-sulfobetaine (PSB), and poly-carboxybetaine (PCB). PSB materials such as 
poly(sulfobetaine methacrylate) (PSBMA) have been wildly studied as medical device 
coating10 and marine coating applications11. PSB materials are generally easy to 
synthesize with low expense. However, the sulfonic acid groups on PSB polymer 
have shown to exhibit toxicity for cells in biomedical applications12. Different from 
PSB materials, the PPC materials are considered to be biomimetic since it had a 
phosphorylcholine head group in each repeating unit, which is found abundant in the 
cell membrane13. Nevertheless, the synthesis procedure of phosphobetaine 
monomers, such as 2-methacryloyloxyethyl phosphorylcholine (MPC), is complex 
with associated high expense14.  
  The PCB has been studied intensively for structural and chemical properties15. 
Compared with PPC and PSB, PCB retains their advantages and shows further unique 
properties that cannot be achieved by other types of zwitterion materials. Surface 




polymer was able to achieve super-low fouling of protein binding (<0.3 ng/cm2) in 
complex physiological environments16-17. In addition, the PCB materials can be 
regarded as biomimetic since the carboxy-betaine chemical group is very similar to 
the glycine betaine, which is one of the solutes in human body fluid that is crucial for 
regulating the osmotic pressure of cells and the estimated daily glycine betaine 
intake of an adult from 0.1 to 2.5 g18. PCB materials have not been found to be toxic 
in both in-vitro and in vivo animal studies19. Furthermore, the carboxyl group of PCB 
can be used to immobilize functional biomolecules or fluorescent dye molecules via 
simple 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide and N-hydroxy-succinimide 
(EDC-NHS) chemistry to extend the functionality of the material20. Lastly, the 
synthesis of the PCB monomer such as carboxybetaine methacrylate (CBMA) and 
carboxybetaine acrylamide (CBAA) is typically a one-step reaction with cheap 
reagents involved21.  
  When using zwitterionic polymers to modify materials for a variety of applications, 
a common challenge exists that most zwitterionic monomers and polymers are 
highly polar and not able to be dissolved in organic solvents. When the materials to 
be modified are hydrophobic, which is frequently the case, it is hard to find an 
appropriate solvent to co-dissolve the zwitterionic monomer/polymer and the 
hydrophobic materials to conducting the modifying reaction22. PCB is unique that it 
has a precursor form, CB-tBu (tertbutyl ester of CB monomer), that could be 
dissolved in many organic solvents such as DMF and acetonitrile, and after the 




This strategy greatly broadens the applications of PCB materials in many application 
scenarios4. 
  Based on the unique super-hydrophilic property, the zwitterionic polymer 
materials had been studied for their potentials in various applications. Surfaces 
coated with zwitterionic polymers were found to effectively reduce more than 95% 
of the adhesion of the protein and microorganism in physiological environments 
such as blood plasma17 and seawaters11. Meanwhile, nanoparticles such as PLGA 
nanoparticles and liposome modified by zwitterionic PCBMA polymers were found to 
show unprecedented colloidal stability and increased circulation time in blood23. 
Zwitterionic polymers stabilized nanoparticles have shown great improvement in 
diagnostic and therapeutic performance compared with nanoparticles stabilized by 
the commonly used polyethyleneglycol (PEG), the golden standard for nanoparticle 
modification24.     
  In addition to anti-biofouling and nanoparticle stabilizing properties, recent 
research revealed many great properties of PCB materials for biomedical 
applications. It was found that a pure PCBMA hydrogel implant was able to resist 
foreign body reaction, which was rarely reported in other common biomaterials such 
as polyethylene glycol (PEG), alginate and Poly-hydroxyethyl-methacrylate (PHEMA)6, 
25. Meanwhile, other research reported that a non-fouling PCBMA hydrogel surface 
enabled stem cells to retain their stem cell phenotype and multipotency, 
independent of differentiation-promoting media, cytoskeletal-manipulation agents, 




controlled by altering the fouling moieties on the PCBMA gel surface8.  
  The focus of this thesis is to study the potentials of the zwitterionic PCB materials 
in solving several key challenges in various applications as stabilizing materials for 
nanoparticles, hydrogels, and surface coatings, respectively. Specifically, this thesis 
involves the work of a one-step synthesis of zwitterionic polymer modified carbon 
nanoparticles, pancreatic islets encapsulation by PCB hydrogel materials and 
subsequent transplantation to achieve long-term diabetic reversal effect, and a 
durable zwitterionic PCB polymer coating for various substrates to resist long-term 
biofilm formation. These subjects are introduced separately in the following 
paragraphs. 
1.1 Zwitterionic polymers for nanoparticles surface modification 
  Anti-fouling polymer materials, especially zwitterionic materials, had been utilized 
to modify nanoparticles to improve their colloidal stability, the key to maintain the 
unique properties of nanoparticles5, 26-28. Super-hydrophilic zwitterionic polymer 
chains attract a dense layer of water molecules to separate nanoparticles from 
aggregation29. Nevertheless, nanoparticle modification with zwitterionic materials is 
not straightforward. Since most zwitterionic materials were unable to be dissolved in 
organic solvent, conjugation of zwitterionic polymers to hydrophobic nanoparticle 
surface was usually hard and involved complex procedures4 (usually involved 5-6 
steps). Easy modification of nanoparticles by super-hydrophilic polymers remained a 
grand challenge in this field. In this work, for the first time, we directly made 




microwave method. The resulting nanoparticle showed superior colloid stability in 
bio-relevant media and even at the freeze-drying conditions. This work will be 
discussed in Chapter 2. 
1.2 Zwitterionic hydrogel for islet encapsulation 
  Polymer hydrogel materials had long been studied as a promising solution for Type 
1 Diabetes (T1D) by delivering insulin independence without immunosuppressant30-33. 
Polymer hydrogel layer was able to provide protection for transplanted from the 
attack of the host’s immune system and are believed to control blood glucose in a 
long term34-35. The major challenge is that current encapsulation materials can well 
protect the islets inside, but they became the target of the host’s immune system 
instead36. A process called foreign body reaction can virtually happen on all existing 
implanted polymer hydrogel37, which would suffocate islets by cutting off the oxygen 
transport from blood and also hinders glucose/insulin transport for the implant to 
achieve therapeutic function38. It remained a challenge for hydrogel materials to 
sustain long-term blood accessibility39. Our research demonstrated that a 
zwitterionic material based hydrogel system was able to perfectly integrate with host 
tissues and remains instantly accessible by circulating blood even after long-term 
implantation at least for five months. It was further demonstrated that with such 
perfect body integration, blood nutrients can be easily transported to the hydrogel 
implant to support the survival and maintain the blood glucose control ability of islet 
cells. The hydrogel/ rat islet constructs have been s.c. implanted to 




independence of the diabetic mice for at least two months. These works will be 
described in Chapter 3.  
1.3 Durable zwitterionic coating for long-term biofilm resistance 
  Zwitterionic polymer coatings had been demonstrated to effectively resist 
microorganism adhesion40-44. The super-hydrophilic anti-fouling polymers prevent 
the attachment of single bacteria cell onto the coating and therefore prevent the 
formation of biofilm45. PCB materials were proved to be efficient in resisting 95% 
Pseudomonas aeruginosa and Staphylococcus epidermis bacteria adhesion and 
reducing the formation of biofilm46. However, unlike hydrophobic polymer coatings, 
super-hydrophilic zwitterionic polymer coatings drastically tend to dissolve into water 
environment47. This leads to gradual exposure of the coated surface over time and 
hinders the use of zwitterionic coating in applications that require long-term 
durability48. Therefore, improving the durability and toughness of zwitterionic 
polymer coating could lead to the success of long-term biofilm resistance. We 
developed several methods to improve the toughness and durability of zwitterionic 
coatings and achieved long-term bacteria biofilm (gram-negative, gram-positive and 
fungi) resistance on various substrates for up to one month challenge in the bacteria 








CHAPTER 2. ONE-STEP SYNTHESIS OF ZWITTERIONIC POLYMERS STABILIZED 
CARBON NANOPARTICLES 
2.1 Introduction 
Zwitterionic polymers had been utilized to modify hydrophobic core to render 
nanoparticle with colloid stability, especially in bio-related environment. However, 
these methods were either involving complex chemical synthesis or low in efficiency 
due to unpredicted NP surface environment. In this Chapter, we designed novel 
strategy to make ultra-stable core-shell nanoparticles directly from zwitterionic 
polymer through one step reaction, completely different from any existing methods. 
Resulting nanoparticles were stable in bio-related environment and even harsh 
freeze-drying condition. This work provides a completely new concept to achieve 
making stable nanoparticles through green chemistry and was expected to inspire 
future functional NPs to be developed. 
Colloid stability is crucial for nanoparticles (NPs) to remain nano-effects in various 
functioning media. NPs with hydrophobic core suffered from aggregation problem 
seriously, especially in bio-related media, which hindered their applications in drug 
delivery and imaging49-52. Typically, anti-fouling polymers, capable of resisting 
nonspecific protein adsorption, were utilized to modify a NP core to prevent it from 
aggregation53. This modification has been done through various methods, e.g., via 
surface adsorption54-55, chemical conjugation4 (e.g., the commonly used “graft-to” 
method to modify the surface with anti-fouling materials such as PEG56-57), and 
particle encapsulation in polymeric micelles58-61, to produce hydrophobic 




chemical synthesis procedures62-63 or were low in efficiency due to unpredicted NP 
surface environment64. As an alternative method to these complex modification 
procedures, we explore the feasibility to make the NPs directly from anti-fouling 
polymers with superior colloid stability. To the best of our knowledge, a hydrophobic 
NP stabilized by anti-fouling polymers made purely from the polymer itself has not 
been reported. 
Inspired by the facile one-step microwave method to fabricate carbon 
nanoparticles65-66, for the first time, we directly made ultra-stable NPs from 
zwitterionic polymers with part of the polymer chain carbonized into the 
hydrophobic core and the rest of the intact polymer as the hydrophilic stabilizing 
shell. Zwitterionic polymers were chosen, since they have demonstrated their 
excellent anti-fouling properties in resisting non-specific binding from proteins, cells 
and microorganisms67. NPs previously modified with zwitterionic polymers showed 
good colloid stability and long-circulation time in blood23. The synthesized 
carbon-core polymer-shell structure was confirmed using NMR and TEM. The directly 
made NPs were found to be ultra-stable in bio-relevant media and even the harsh 
freeze-drying conditions (with no cyro-protectant in presence), note that most 
existing NPs could not survive from such extreme lyophilizing conditions. 
2.2 Materials and Methods 
2.2.1 Materials  
Methacryloyloxyethyl phosphorylcholine (MPC 97%), 2-Methacryloyloxy-ethyl 




(98%), 2-(Dimethylamino) ethyl mathacrylate (DMA 98%), Amberlite IRN78 hydroxide 
form, Quinine hemisulfate salt monohydrate (98%), Acetone (99.5%), Phosphate 
buttered Saline tablet (PBS), Albumin from bovine serum (BSA 98%) and Fibrinogen 
from bovine plasma (65-85%) were purchased from Sigma-Aldrich, St. Louis, MO. 
Ethyl Ether Anhydrous (99.9%) and Boric Anhydride were obtained from Fisher 
Chemical. Co. Acetonitrile anhydrous (99.9%) was purchased from ACROS Organics. 
B-Propiolactone (95%) was supplied by Wako Pure Chemical Industries Ltd. 
Deuterium Oxide (D2O 99.9%) was obtained from Cambridge Isotope Laboratories, 
Inc. USA. PD-10 desalt columns were purchased from GE Healthcare, UK. Boric 
Anhydride was utilized to dry acetone and all other chemicals were used without 
further purification. 
2.2.2 Synthesis of PSB NPs, PMPC NPs, PCB-2 NPs 
5 mg photo-initiator was added to 5 ml degassed DI water and 100 mg SBMA, MPC, 
CBMA-2 (synthesis as previous report) monomer was dissolved 0.5 ml photo-initiator 
solution. Polymerization was initiated by exposing the solution under UV (365 nm, 6 
W) for 2 minutes with stirring. Then resulted polymer solution was diluted to 2.5 ml 
and went through salt filter column (cutoff molecular weight 2000) to remove 
residue monomer and initiator. Pure polymer (Mw 10k) solution was poured into a 
flask and the flask was set in the center of a domestic microwave oven. After heating 
under 1200 W for 5 minutes, light brown substance emerged in the bottom of the 
flask. 10 ml DI water was added and stirred for 1 h. Resulting solution was 




brown NPs solution with florescence under UV. The general yeild was 56.65%. 
2.2.3 Synthesis of PCB-1 NPs 
CBMA t-butyl monomer was synthesized as previous report4. 200 mg of CBMA tbul 
monomer was hydrolyzed in 2 ml TFA for 5h. TFA solution was dropped in anhydrous 
ethyl ether to remove TFA and precipitate CBMA-1 zwitterionic monomer. After 
vacuum dried, monomer was dissolved in 0.5 ml photo-initiator solution described 
above in ice bath. Basic resin was used to adjust solution pH to 7 and the yielding 
solution was exposed under UV to initiate polymerization. The resulting PCB-1 was 
similarly purified and made into NPs as described in the last section.  
2.2.4 NPs purification 
2 g sucrose,was dissolved in 10 ml DI water to prepare sucrose stock solution. 1.4 
ml sucrose solution was added to a centrifuge tube and 0.1 ml NPs raw solution was 
slowly added to obtain a well-defined NP region on the top of sucrose solution. 
Centrifuge the tube for 1 h at 15000 rpm at room temperature and expose the tube 
to UV. NP region in the sucrose column showed blue florescence and was collected 
using a pipette. The collected solution will go through a PD-10 column to remove 
contaminated sucrose.  
2.2.5 Nanoparticle Characterization: 
The morphology and microstructure of the PMPC NPs and PCB-1 NPs were 
examined by transmission electron microscopy (TEM) on JEOL 2010 TEM with LaB6 
Filament Gun (JEOL Ltd. Tokyo, Japan) under accelerating voltage of 200 kV. Purified 




carbon film to make TEM sample. Nuclear Magnetic Resonance H1 spectrum of 
zwitterionic polymer and purified NPs were conducted on Varian Mercury-400 MHz 
NMR. Polymer and purified NPs were lyophilized and dissolved in Deuterium Oxide 
(D2O). Molecular weight of the MPC and CB-1 polymer are determined by a Waters 
Alliance 2695 Separations Module equipped with a Waters Ultrahydrogel Linear 
column and a Waters 2414 reflex detector. The mobile phase was PBS buffer solution 
at a flow rate of 0.7 ml/min at 35 °C. Poly(ethylene oxide) from Polymer Laboratories 
were used as standards. UV absorption of NPs was conducted on a Multiskan GO 
UV–Vis Spectrophotometer (Thermo Scientific, USA). 
2.2.6 Fluorescence Property measurement 
The maximum absorptions were 354 nm for PMPC NPs and 367 nm for PCB-1 NPs. 
Maximum emissions are 436 nm for PMPC NPs and 455 nm for PCB-1 NPs. Quantum 
yield of the PMPC NPs and PCB-1 NPs were determined by comparative method. 
Quinine hemisulfate in 0.1 M H2SO4 was utilized as the standard whose QY was 
reported to be 54%. The integrated fluorescence intensity is the area under the PL 
curve in the wavelength range from 380 to 650 nm with 365 nm excitation. Absolute 
values were calculated according to the following equation: 
 
Where ST denotes the standard, Grad is the gradient from the plot of integrated 
fluorescence intensity vs absorbance, and η is the refractive index of the solvent. To 
prevent the re-absorption effect, absorbance in the 10 mm fluorescence cuvette 




and PCB-1 NPs were 8.92 ± 0.60 % and 7.02 ± 0.59 %, respectively. 
2.2.7 MTT cytotoxicity assays 
The cytotoxicity of the PMPC NPs and PCB-1 NPs was determined by MTT assay. 
NIH/3T3 Fibroblast were grown in 96-well plates in full Dulbecco's Modified Eagle's 
Medium and 10% FBS under 5% CO2 at 37 °C to allow 80-90% confluence. For each 
well, cells were washed with PBS and incubated with 200 μl full medium containing 
varied concentration of PMPC NPs, PCB-1 NPs and CA NPs for 24 h. Cells were 
washed with PBS to remove NPs and incubated with 100 μl full medium plus 50 μl of 
12 mM MTT stock solution for another 4 h. Then, MTT containing medium was 
replaced with 150 μl DMSO to dissolve the formed crystal at 37 °C for 10 min. 
Absorbance (Abs) was measured at 570 nm with pure DMSO as the blank reading. 
Cells with no NPs incubation were used as the controls and cell viability upon NPs 
treatment was estimated in triplicate: cell viability (%) = Abssample / Abscontrol x 
100. 
2.3 Result and discussion  
The synthetic route to core-shell zwitterionic NPs composed of one single step, 
microwave heating of zwitterionic polymers (Figure 2-1). Typically, Zwitterionic 
polymers were synthesized through UV initiated polymerization of respective 
monomers. Then, a beaker containing 100 mg of zwitterionic polymer (Mw 8-10 KDa) 
in 5 ml DI water was placed at the centre of the rotation plate of a 1000 W 
microwave oven and heated for 5 minutes. As water evaporated, light brown 




simple, facile and green, however, there are several obstacles to overcome before 
obtaining the targeted core-shell zwitterionic NPs. 
The primary challenge is that microwave oven heating can’t be easily controlled 
and resulting polymer NPs are contaminated with unreacted polymers and have 
broad size distribution (PDI > 0.6 as measured by dynamic light scattering, DLS). 
Conventional purification methods such as centrifugation, filtration, or dialysis can’t 
effectively remove the contaminating polymers or obtain homogeneously sized NPs. 
We found a sucrose gradient centrifugation method can be effective to purify the 
rough products68. NPs migrate under the centrifugation force with their migration 
pattern retained by sucrose while linear free polymers barely moved and stayed on 
top of the sucrose column. This was confirmed by control experiment where free 
polymer solution alone was loaded on top of the sucrose column and DLS results 
showed no polymer presented in the NPs layer. By exposing the centrifuge tube to 
UV light, polymer protected NPs can be visualized and retrieved (fluorescent 
property will be discussed below). Further removal of sucrose was achieved by using 
a PD-10 column and highly purified polymer protected NPs (free from unreacted 
polymers with narrow size distribution, diameter < 30 nm, PDI < 0.15) can be 
obtained. 
The next challenge we met is that zwitterionic polymer chosen should stand high 
temperature of the microwave heating reaction. While part of the polymer 
carbonized into the NP core, the other part of the polymer should be thermally intact 




poly(sulfobetaine) (PSB)69 and poly(carboxybetaine)-2 (PCB-2) (Table 2-1), two 
common zwitterionic polymers we previously worked on, was not successful; the 
obtained NPs were positively charged as indicated by zeta-potential measurement in 
water. This could be explained by the thermo-instability of SB and CB-2 units; when 
heated at high temperature, the quaternary amine group tends to undergo 
“elimination reaction” splitting into a tertiary amine and an acrylic group70. The 
resulting NPs thus showed positive net charges due to the protonated tertiary 
amines formed on the protecting polymer shell. By contrast, poly 
-(2-methacry-loyloxyethyl phosphorylcholine) (PMPC)71-74 and poly 
-(carboxybetaine)-1 (PCB-1)75 polymers were found to render resulting NPs with 
zwitterionic property, as characterized by a slightly negative zeta potential of the 
resulting NPs. It should be noted that their parent zwitterionic polymers gave similar 
negative zeta potentials in the control experiment (Table 2-1). Among four kinds of 
polymer derived NPs, only PMPC and PCB-1 NPs were chosen for further study due 
to their zwitterionic shell nature. 
It was hypothesized that the zwitterionic polymer was partially burnt into the 
carbon core while the remaining part forming a super-hydrophilic shell. The structure 
of the purified zwitterionic NPs was further examined using transmission electron 
microscopy (TEM) and nuclear Magnetic resonance H1 (NMR). Organic molecules are 
known for their carbonization under microwave heating conditions76-77. Carbon core 
structure for PCB-1 NPs and PMPC NPs could be detected under the TEM (Figure 2-2). 




respectively. NMR results (Figure 2-3) showed a perfect match between the peaks of 
polymer shell of NPs and the parent free polymers, indicating that the protecting 
polymer structure remained intact on the NP surface. 
For potential biological applications, NPs have to be stable in complex 
environment where bio-elements (e.g., proteins) were present. It is expected that 
the synthesized zwitterionic NPs are well protected from aggregation by the 
zwitterionic shell in the bio-related media. As non-zwitterionic polymer NP controls, 
we synthesized CA NPs, from citric acid and ethylenediamine through the same 
microwave method (a well-established fluorescent NP system with ultra-high 
quantum yield78), and purified it via the same sucrose centrifugation procedure. The 
resulting CA NPs had slightly negative zeta potential (-1.78 mV), similar to 
zwitterionic polymer stabilized NPs, but were lack of a zwitterionic polymer shell 
surface. For colloid stability testing, purified PMPC NPs, PCB-1 NPs and CA CNPs (size 
< 30 nm PDI < 0.18) were placed in PBS (phosphate buffered saline, salt 
concentration 153 mM), PBS solution of 5 wt% bovine serum albumin (BSA) and PBS 
solution of 5 wt% fibrinogen from bovine plasma. The sizes for NPs were measured 
as a function of time (Figure 2-4(a) and Figure 2-5). No obvious size increase 
appeared in any of the zwitterionic polymer NPs groups while CA NPs aggregated 
drastically. It is a general trend that particles tend to be less stable in high salt 
concentration solution79. Zwitterionic PCB-1 NPs, however, retained its original size in 
a solution with salt concentration as high as 500 mM in a 40-min study (i.e.). CA NPs 




Long-term stability study (Figure 2-4(b)) showed that both PMPC NPs and PCB-1 NPs, 
after one week incubation in PBS, have no significant size increase while CA NPs 
continuously aggregated. 
Lyophilization, a necessary procedure for NP storage and precise weighing, 
introduces harsh interaction among individual NPs, causing aggregation that could 
not be segregated even under sonication. To the best of our knowledge, NPs even 
protected by anti-fouling polymers are very rare to survive from lyophilization 
induced aggregation. We used lyophilization conditions to further push the limit of 
stability performance of the zwitterionic core-shell particles. PMPC NPs, PCB-1 NPs, 
and CA NPs were lyophilized without adding any cryoprotectant and re-dissolved in 
DI water and their sizes were measured using DLS (Figure 2-6). CA NPs aggregated 
substantially after freeze-drying while zwitterionic NPs survived such harsh condition 
by maintaining the particle size. We have previously observed that PCB-1 protected 
PLGA NPs can sustain the original size through lyophilization, while other NP 
protecting technology (such as PEG-PLGA) can’t but require the addition of 
cyro-protectant (e,g., 10% sucrose)80. It was believed that zwitterionic polymers 
strongly bind water molecules to prevent hydrophobic interactions among carbon 
cores in this case, and keep them apart even in a highly dehydrated environment22. 
With excellent stability, both in bio-relevant media and harsh freeze drying 
conditions, we demonstrated the effectiveness of our strategy to render NPs 
ultra-stabile properties. 




conducted (Figure 2-7(a)). NIH/3T3 cells remained more than 85% and 80% viability 
in PMPC NPs and PCB-1 NPs, respectively, at concentration as high as 10 mg/ml, 
while CA NPs were toxic to cells (30% viability) at concentration as of 5 mg/ml. It is 
worth-mentioned that the synthesized NPs had fluorescent property (Figure 2-7(b)). 
Under UV excitation, Both the PCB-1 NPs and PMPC NPs exhibited blue light. It was 
hypothesized that the fluorescent property was related to the core-shell structure, 
which was previously reported as surface-passivation mechanism81. The fluorescent 
property can lead to potential imaging applications of the resulting zwitterionic 
NPs82-83. 
In summary, we have demonstrated a novel strategy to make core-shell NPs with 
superior stability directly and solely from anti-fouling zwitterionic polymers through 
single step of microwave heating. Only those zwitterionic polymers, that are stable 
through high temperature microwave heating can produce zwitterionic polymer 
shell-carbon core NPs, which can be further purified through sucrose gradient 
centrifugation. It was found that zwitterionic NPs maintained excellent colloid 
stability in various bio-relevant media, and even under the harshest lyophilization 
condition. With undetectable cytotoxicity, the new strategy will lead to ultra-stable 
NPs for drug delivery and imaging application. We expect this green chemistry in 








Figure 2-1 Illustration of making carbonized core- zwitterionic polymer shell NPs 









Table 2-1 Structures for zwitterionic polymers involved and zeta-potentials for these 
free polymers and the resulting NPs 
 
 































































Figure 2-2 (a) TEM image and statistic size distribution of PCB-1 NPs (scale bar: 100 










Figure 2-3 (a) NMR spectra of parent CB-1 polymer and synthesized PCB-1 NPs, (b) 










Figure 2-4 (a) short-term and (b) long-term colloid stability of PCB-1, PMPC, and CA 






















































Figure 2-7 (a) MTT results of CB-1, MPC and CA NPs. (b) Fluorescent property of 









CHAPTER 3. ZWITTERIONIC HYDROGEL IMPLANT PROMOTES FUNCTIONAL BLOOD 
VESSELS GROWTH AS GOOG AS NATURAL BODY SYSTEM 
3.1 Introduction 
In this chapter, we will describe the zwitterionic polymer hydrogel as the first 
synthetic material ever known promoting functional neovascularization as good as 
natural body system. A zwitterionic carboxy betaine containing hydrogel was found 
to promote vascularization at the subcutaneous (s.c.) site to the same density level 
as normal tissue, and to maintain that high-level vasculature for at least 6 months. 
The newly formed blood vessels were perfused and they approached the implanted 
zwitterionic gel surface as close as below 20 micrometers away. Consequently, the 
zwitterionic hydrogel was highly accessible by circulating blood, even after 5 months 
of implantation. This finding was highlighted by using zwitterionic hydrogel in 
encapsulating islet of Langerhans for the treatment of Type 1 diabetes. The 
zwitterionic hydrogel based novel system remarkably outperforms the 
state-of-the-art technology using alginate encapsulating materials at highly 
challenging s.c. site. 
Implantable devices based on biopolymers are wildly utilized in biomedical fields 
such as cell encapsulation84-85, monitoring sensor coating86-87, controlled drug 
release88 and tissue engineering89. Most of these applications require adequate body 
fluid exchange, in which blood was the most crucial to enable the exchange of gasses, 
nutrients, and metabolites between the blood and device, to sustain the survival of 
tissue/cell grafts and achieve monitoring or therapeutic effect90-93. Blood accessibility, 




comparable density of blood vessel with normal tissue is considered to be ideal94-95. 
Nevertheless, most of the biomaterial implants could not escape from foreign body 
reaction and blood accessibility was cut off soon after transplantation96-97.  
A number of researches had been done to increase blood vessel formation for 
implanted materials. It was found that materials with microarchitecture were able to 
promote neovascularization in surrounding area98, particularly at pore sizes of 30-40 
µm99, but the resulting vessel density is still far below regular tissue level. Delivery of 
growth factors (e.g., vascular endothelial growth factor and fibroblast growth 
factors100-103), angiogenic genes104, and stem cells105-106 facilitates neovascularization 
and has been studied for combinational delivery with cells in transplantation. 
However, the blood vessels promoting effect was not able to be maintained when 
the growth factors or gene were used out107. The high cost and potential safety issue 
also hindered these methods from further advancement in applications. 
Here, we developed hybrid hydrogel material containing zwitterionic carboxy 
betaine (CB) moieties to solve the blood accessibility challenge. A zwitterionic 
hydrogel material, after subcutaneous (s.c.) implantation, supports the growth of 
new blood vessels to the same density level as naturally healed wound and healthy 
tissue, and maintains such high-density vasculature for a long-term (up to 6 months, 
the longest time point tested). The newly formed blood vessels were functionally 
perfused, and the nearest vessels are within 20 μm distance from the implant 
surface. Therefore, the zwitterionic hydrogel implants are highly blood accessible, as 




even after 5 months of implantation. This is the first synthetic material ever known 
promoting functional neovascularization as good as natural body system. To 
highlight the implication of this finding, the zwitterionic hydrogel was utilized to 
encapsulate rat islets of Langerhans and s.c. implanted in diabetic mice. We 
observed that islets encapsulated by state-of-the-art alginate materials (both high 
guluronate and high mannuronate) failed to control blood glucose starting at day 
~10 at the challenging s.c. implantation site, while zwitterionic hydrogel/islet 
remarkably reversed diabetes through the entire 80 days of implantation. We expect, 
with natural tissue-like blood accessibility, the zwitterionic hydrogel is a promising 
platform to improve the long-term performance of most current implantable 
devices. 
3.2 Materials and methods 
3.2.1 Materials 
CBAA monomers were synthesized as previous reports108. PEGDA 10K was 
purchased from Laysah Bio, Inc. (Lot# 136-18). HEMA monomers were obtained from 
ACROS ORGANICS (New Jersey, USA). Sterile and low endotoxin alginate SLG20 and 
alginate SLM100 were purchased from FMC Biopolymer. Evans Blue dye and 
Fluorescein isothiocyanate-dextran (FITC-dextran) were obtained from Sigma-Aldrich. 
(St. Louis, USA). 
3.2.2 Synthesis of hydrogel materials 
The PCBAA and PHEMA hydrogel were fabricated by UV initiation of monomer 




2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (I-2959) and 1% crosslinker 
(MBAA). Polyethylene (glycol) diacrylate (PEGDA) hydrogel was synthesized as 
reported previously that PEGDA solution (10% in weight ratio) was crosslinked under 
UV in the presence of 0.2% UV initiator (I-2959). Alginate SLG20 and alginate SLM100 
hydrogel were formed by mixing the alginate solution (1.4% in 0.9% NaCl) with 20 
mM BaCl2 solution. All hydrogel samples were equilibrated in sterile 
phosphate-buffered saline (PBS) for at least five days with frequent change of PBS to 
remove all unreacted small molecule. Before implantation, all samples were shaped 
into discs form (D=5 mm) with 1 mm in thickness either using a punch or lancet. The 
endotoxin level of implant hydrogels was evaluated using a Limulus Amebocyte 
Lysate (LAL) endotoxin assay kit (Cambrex Bioscience) with a detection limit of 0.06 
endotoxin units (EU)/ml. 
3.2.3 Implantation of hydrogel materials  
All animal experiments followed federal guidelines and were approved by the 
IACUC at Wayne State University. C57BL/6 mice (male, 20-30g, from Jackson’s Lab) 
were anesthetized using isoflurane and received meloxicam analgesia. The surgical 
site (dorsal skin) was shaved and prepped with three alternating scrubs of betadine 
and alcohol. On prepped animal, a single incision (1.5-2 cm) was made through the 
dorsal skin.  Bilateral subcutaneous pockets are created by blunt dissection through 
the incision for placement of one material sample per pocket. After implantation, 




Hydrogel implants were kept in mice for a maximum of 6 months before further 
testing.  
3.2.4 Histology study: Blood vessel staining and density calculation  
At pre-determined time points, mice with implants were euthanized by CO2 
asphyxiation. The hydrogel samples together with the surrounding tissue were 
excised by cutting around the area with scissors and scalpels. The explanted samples 
were then fixed in zinc fixative for 2 days and embedded in paraffin wax. 5 µm 
sections were cut and mounted onto slides for histological staining. Blood vessels 
were stained brown using rat anti-mouse MECA-32 antibody kit from BD Biosciences 
(dilution 1:20; catalog no. 550563), which is an endothelial cell biomarker. Blood 
vessel density was calculated by counting the average blood vessel number in 0.2 
um2 area with 6 random repeats.   
3.2.5 Immunofluorescence staining of macrophage phenotypes 
Triple-label immunofluorescence staining was employed to examine phenotypes 
of macrophages near to the implant/tissue interface, following the previous 
protocol6. Macrophage cells were identified by F4/80 antigen. Phenotype markers 
include iNOS, IL-1β, TNF-α, and IL-12 (pro-inflammatory markers), and MMR, Arg1, 
IL-10, and TGFβ1 (anti-inflammatory markers). The tissue slides were incubated with 
three primary antibodies (rat anti-mouse F4/80 antibody, one pro-inflammatory 
antibody (rabbit or goat anti-mouse), and one anti-inflammatory antibody (goat or 
rabbit anti-mouse)), followed by incubation with three secondary antibodies labeled 




F4/80 antibody (BM8) (dilution 1:50; catalog no. 14-4801-82, eBiosciences), rabbit 
anti-mouse iNOS antibody (dilution 1:50; catalog no. ab15323, Abcam), goat 
anti-mouse IL-1β antibody (M-20) antibody (dilution 1:50; catalog no. sc-1251, Santa 
Cruz Biotechnology), rabbit anti-mouse TNF-α antibody (dilution 1:25; catalog no. 
ab9739, Abcam), goat anti-mouse IL-12 antibody (dilution 1:50; catalog no. 
NB600-1443, Novus Biologicals), goat anti-mouse MMR antibody (dilution 1:50; 
catalog no. AF2535, R&D Systems), rabbit anti-mouse Arg1 antibody (H-52) (dilution 
1:50; catalog no. sc-20150, Santa Cruz Biotechnology), goat anti-mouse IL-10 
antibody (M-18) (dilution 1:50; catalog no. sc-1783, Santa Cruz Biotechnology), 
rabbit anti-mouse TGFβ1 antibody (V) (dilution 1:50; catalog no. sc-146, Santa Cruz 
Biotechnology). Secondary antibodies include: donkey anti-rat IgG (dilution 1:200; 
catalog no. A-21209, Invitrogen), donkey anti-rabbit IgG (dilution 1:200; catalog no. 
A-21206, Invitrogen), and donkey anti-goat IgG (dilution 1:200; catalog no. A-21081, 
Invitrogen).  For isotype control, rat IgG (dilution 1:80; catalog no. sc-2026, Santa 
Cruz Biotechnology), goat IgG (dilution 1:80; catalog no. sc-2028, Santa Cruz 
Biotechnology), and rabbit IgG (dilution 1:80; catalog no. sc-2027, Santa Cruz 
Biotechnology) were used as primary antibodies. For negative control, no primary 
antibodies were used.  
3.2.6 FITC-dextran injection and histology study  
At pre-determined time points, mice with implants were anesthetized using 
isoflurane. 200 µl FITC-dextran/PBS solution (2 mg per 20 g mouse) was injected 




asphyxiation. The hydrogel samples together with the surrounding tissue were 
collected and then fixed in zinc fixative for 2 days and embedded in paraffin wax. 5 
µm sections were cut and mounted onto slides, which was directly visualized under a 
fluorescent microscope with an excitation wavelength of 488 nm.  
3.2.7 Evans Blue injection for accumulation study  
At pre-determined time points, mice with implants were anesthetized using 
isoflurane. 15 mg Evans Blue in PBS buffer was administrated by i.v. injection for a 
mice with 25 g body weight. 5 min after injection, mice were euthanized by CO2 
asphyxiation. The hydrogel samples were explanted excluding the surrounding tissue 
and immediately exposed to UV (365 nm) for imaging.   
3.2.8 Islet isolation  
Rat islets were isolated using a method established by Lacy and Kostianovsky109 as 
well as others110-113 and modified by our lab. Briefly, Sprague-Dawley rats (male, 
275-300g, from Charles River Lab) were euthanized by CO2 and their bile ducts were 
cannulated with an injection of Collagenase P solution. The distended pancreases 
were removed and further digested by Collagenase P at 37 oC. Digested pancreases 
were quenched with cold PBS, washed, filtered using a 450 µm sieve, and subjected 
to Histopaque 1077/PBS gradient purification. Islet layer was taken and further 
purified by hand-picking islets. Resulting islets were counted and cultured in RPMI 
1640 media with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C in 
humidified air containing 5% CO2.  




To encapsulate a large number of islets by PCBAA hydrogel for therapeutic 
purpose, the isolated rat islets will be first encapsulated by 1.4% Alginate SLG20 after 
mixing the islet/alginate preparation with 20 mM BaCl2 solution, and then be shaped 
into disks of 3 mm in diameter and 1 mm in thickness. The islet containing small 
disks will be placed between two glass slides separated by Teflon spacers (2 mm in 
thickness), suspended in a pre-gel solution (containing zwitterionic CBAA monomer, 
MBAA crosslinker, and photoinitiator I2959 in PBS), and chemically crosslinked at 
365 nm UV. The resulting hydrogel sheets will be removed and equilibrated in cell 
culture medium, and tailored into macro disks using a 5-mm biopsy punch for 
transplantation (islets encapsulated within the 5 mm PCBAA disk). SLG20/islet and 
SLM100/islet controls were obtained by mixing the islet/alginate preparation (1.4% 
alginate concentration) with 20 mM BaCl2 solution, and then be shaped into disks of 
5 mm in diameter and 2 mm in thickness.  
C57BL/6 mice (male, 20-30g) received a daily i.p. injection of 5 mg/ml streptozocin 
(STZ) at 50 mg/kg for 5 consecutive days. STZ-mice were placed on a non-fasted 
regular diet. 17 days after the first injection, weight and blood glucose were 
measured to confirm diabetic status. Only mice whose non-fasted blood glucose 
levels were above 300 mg/dL for two consecutive days were considered diabetic and 
underwent transplantation. PCBAA/islet, SLG20/islet, and SLM100/islet disks were 
s.c. implanted in diabetic mice at day 0 following the implantation procedure 
described above. After implantation, the animals’ blood was sampled three times a 




tested using a commercial glucometer (Clarity One, Clarity Diagnostic Test Group). 
Typically, the mice blood glucose was observed to drop one or two days after the 
implantation. Mice with a non-fasted blood glucose below 200 mg/dL were 
considered normoglycemic. Transplanted mice maintaining normoglycemia (i.e., 
received PCBAA/islet) and those returning to hyperglycemic state (i.e., received 
SLG20/islet and SLM100/islet) were subject to explantation. Explanted islets were 
stained by Live and Dead staining kit (Life technology) to visualize the survival of 
islets. 
3.2.10 Glucose-stimulated insulin secretion (GSIS) assay 
Explanted hydrogels with islets encapsulated were pre-incubated for 1 h in 
FBS-free RPMI 1640 containing 2.8 mmol glucose in a 6-well plate at 37°C incubator 
in 5% CO2. In the following 3 hours, RPMI 1640 medium with 2.8 mmol glucose, 28 
mmol glucose, and 2.8 mmol glucose was added consecutively, 1 h respectively. 
After each incubation, the media was collected and stored at -20 °C for future insulin 
concentration determination. The rat insulin concentration in the culture media was 
evaluated using Mercodia ultrasensitive rat insulin kit (Uppsala, Sweden) with three 
repeats for every group.  
3.2.11 Statistical Analysis 
n = 6 was used for mice per time point or per treatment group unless specified 
otherwise. The sample size was selected according to previous reports. All tested 
mice were included in analyses except for ones with unforeseen sickness or 




to performed experiments. Representative images illustrated are based on n = 3 
mice per treatment group unless specified otherwise. Most data were normally 
distributed and similar variance was determined for groups that are compared. 
Analysis includes unpaired two-tailed t-test and one-way analysis of variance 
(ANOVA) with Bonferroni multiple-comparison correction. For data not following 
normal distribution, non-parametric Mann-Whitney test was used. *: P < 0.01, **: P 
< 0.001, ***: P < 0.0001 and n.s: no significant difference. For all statistical analyses, 
significance was accepted at the 95% confidence level. 
3.3 Results  
3.3.1 Implanted zwitterionic hydrogel healed like a natural wound, and promoted 
vascularization to the same density level as normal tissue. 
The zwitterionic hydrogel was made from zwitterionic carboxybetaine acrylamide 
(CBAA) monomer (synthesized as previously documented108) and a widely used 
N,N-methylenebis(acrylamide) (MBAA) crosslinker through ultraviolet (UV) induced 
crosslinking (structure in Figure 3-1(a)). The resulting hydrogel was equilibrated in 
phosphate buffered saline (PBS) and punched into disks of 5 mm in diameter and 1 
mm in thickness. Zwitterionic hydrogel disks along with other hydrogel controls of 
the same dimension were then subcutaneously (s.c.) implanted on normal healthy 
mice. One month after implantation, hydrogel samples with surrounding tissue were 
collected for histology study. An incised subcutaneous wound healed for one month 
(no hydrogel implanted) and a normal healthy subcutaneous tissue were also 




MECA-32 on endothelial cells, blood vessels can be visualized (shown by brown color) 
and their density can be calculated.  
The major finding was that the zwitterionic hydrogel implant promoted blood 
vessel formation which was similar to healthy tissues in vessel density. It was clearly 
showed that new blood vessels formed near to the zwitterionic PCBAA hydrogel 
surface (Figure 3-1(b)) with a vessel density comparable to physiologically healed 
and healthy tissues (no significant difference at p > 0.58; Figure 3-1(c)). On the 
contrary, the Alginate SLG20 hydrogel, PEGDA 10K hydrogel and PHEMA hydrogel 
(made from 2-hydroxyethyl methacrylate (HEMA)) had much fewer 
neovascularization in the surrounding area; this is significantly different from PCBAA 
hydrogel (p < 0.0001). It was worth mentioning that these control materials (alginate, 
PEG, and PHEMA) have been intensively studied for implantation purposes, such as 
for tissue engineering114-115, device coating116-117, and cell therapies118-126. It was 
further observed that such high level of blood vessel density induced by the 
zwitterionic hydrogel can last at least 6 month in the transplantation study (no 
significant change over time at p > 0.31; Figure 3-1(d); representative histological 
images shown in Figure 3-2). 
We did not observe a sign for uncontrolled blood vessel formation in the 
surrounding area of the zwitterionic hydrogel, indicating that the hydrogel was not 
like a tumor that induces uncontrolled neovascularization. A melanoma tumor was 
developed by s.c. injection of 1x105 murine B16F10 cells s.c. to the back on health 




histological analysis using anti-MECA-32 blood vessel staining. It was found that the 
tumor blood vessels showed structurally disordered, abnormal morphology (in 
agreement with the literature127) and their density was estimated to be at least 
three times of that of normal tissue and the tissue interfaced with PCBAA hydrogel 
(Figure 3-3). 
3.3.2 The newly formed blood vessels were perfused, and approached the 
implanted zwitterionic hydrogel surface as close as below 20 µm away. 
Based on the finding that the implanted zwitterionic PCBAA hydrogel induced 
vascularization to a density level comparable to that of a naturally healed wound and 
normal tissue level, it is essential to know whether these newly formed blood vessels 
are functional and perfused with circulating blood. To address this question, we 
injected FITC-dextran solution through the tail vein to healthy mice previously 
received the s.c. implant of different hydrogel materials for one month. 300 seconds 
following the injection, implanted hydrogel samples with surrounding tissue were 
collected for tissue sectioning (Figure 3-4(a)). Using a fluorescent microscope, it was 
discovered that the newly formed vessels were highly perfused with function, which 
was proved by the green dye in the lumen of the vessels in the surrounding of PCBAA 
hydrogel. For alginate and PEGDA hydrogel surface tissue, however, no significant 
amount of green-labeled blood vessel can be observed (Figure 3-4(b)). The density of 
neovascularization could also be calculated based on the green-labeled tissue slides 
(Figure 3-5), and was found to be comparable to MECA-32 staining results (Figure 




It is particularly worth noting that the newly formed blood vessels approached the 
zwitterionic hydrogel surface as close as possible. We created a penetrating hole (1 
mm in diameter) in the center of the hydrogel disk, or an inter-space between two 
identical disks (Figure 3-4(d)), and s.c. implanted them for one month. Mice then 
received a tail-vein injection of FITC-dextran, and 5 min later hydrogels together with 
surrounding tissues were histologically analyzed. It was obvious that new blood 
vessels grew into the holes and narrow space between zwitterionic hydrogel 
surfaces after one-month implantation (Figure 3-4(c)), and also maintained their 
presence after two-month implantation (Figure 3-6). We further measured how 
close these new functional vessels were to the zwitterionic surface in the cases of 
hydrogel disks, holes, and interspaces, and found that the nearest blood vessels 
were typically within a perpendicular distance of 20 µm from the gel surface (Figure 
3-4(e)). Considering a typical animal cell size of 10-20 µm in diameter, the 
zwitterionic implant surface is expected to be highly accessible by the blood with 
only one or a few cell layers in between. 
3.3.3 Implanted zwitterionic hydrogel was highly accessible by circulating blood for 
up to five months. 
The function or tissue and organ were supported by the blood that transports 
oxygen, nutrient and metabolic waste128. It will be ideal that an implantable device 
can achieve a similar level of blood accessibility as regular tissue to sustain efficient 
transport and communication between the device and its environment. Based on the 




zwitterionic gel surface down to 20 µm range, we expect the hydrogel can be easily 
accessible by circulated blood components. This was evaluated by quantifying the 
freshly injected dye molecules that circulated through blood and accumulated to the 
implanted hydrogels. Healthy mice received s.c. implantation of hydrogel samples 
for up to 5 months, and was then injected with Evans Blue through tail vein. Evans 
blue was a nontoxic dye that was widely applied as a contrasting agent to improve 
resolution of small veins129. 5 min after injection, mice were sacrificed and hydrogel 
samples were immediately explanted, visualized under UV (Figure 3-7(a)), and 
quantified for dye accumulation (Figure 3-7(b)). It was found that all tested hydrogel 
samples implanted for 1 day were not able to effectively recruit the dye due to the 
destruction of nearby blood vessels during the implantation surgery. For zwitterionic 
PCBAA disk, the dye accumulation was found to be significant at 2 weeks after 
implantation (Figure 3-8), and reached its maximum during the 2 to 5 months 
post-implantation window. By contrast, non-zwitterionic controls, PEGDA 10K and 
Alginate hydrogels, exhibited negligible fluorescent intensity during the entire study 
period (p < 0.0001). This result indicates that the implanted zwitterionic hydrogel is 
able to maintain superior blood accessibility for a long term, which has rarely been 
obtained by known implanted synthetic materials. 
3.3.4 zwitterionic hydrogel enabled the survival and function of encapsulated 
xenograft islets and improved therapeutic outcome at subcutaneous site 
To highlight the implications of our findings, we studied whether the unique and 




vessel density and superior blood accessibility, can improve the performance of an 
implantable device. Particularly we employed zwitterionic hydrogel for islets of 
Langerhans (islets) encapsulation and subsequent xenograft transplantation. 
Conventional biomaterials such as alginate and PEG have been widely used to 
encapsulate/immuno-isolate the islets, but their therapeutic potential was 
jeopardized since nutrients and oxygen can hardly reach the implanted device to 
sustain the cell viability130-131. When islets are transplanted at s.c. site, their viability 
is even worse since s.c. site is generally less blood accessible comparing with other 
locations, such as intraperitoneal (i.p.) site132. It has been reported that alginate 
based materials sustained islet survival at the i.p. site but failed at the s.c. site133, and 
the i.p. location was mostly used in evaluating performance of islet encapsulating 
devices134-135. Regarding the challenge above, we expect that islets transplantation 
outcome at the convenient s.c. site can be significantly improved through 
zwitterionic hydrogel encapsulation.  
Our study involved two phases. At phase one, PCBAA and control hydrogel 
materials (Alginate SLG20 and PEGDA 10K) were used to encapsulate a few rat islets 
and the hydrogel/islet constructs were s.c. implanted in healthy mice. Each 
encapsulating construct included 3-6 islets in order to tract and identify the size, 
location, and survival condition of each islet after explantation. It was found that 
islets encapsulated by zwitterionic PCBAA hydrogel were healthy under a microscope 
after one-month implantation, however, islets in the Alginate and PEGDA hydrogels 




constructs were further challenged continuously by three glucose concentration 
levels (2.8, 16.7, 2.8 mmol; each for 1 h) to evaluate the insulin producing capability 
of the transplanted islets in a glucose challenge methods (Figure 3-9). It was showed 
that islets encapsulated in PCBAA hydrogel sustained their glucose response 
capability after 30 days in mice (no significant difference, p > 0.53), but control 
materials failed to render islets normal GSIS function (p < 0.0001).  
At phase two study, we encapsulated larger amount of rat islets and examined 
whether zwitterionic hydrogel encapsulation outperformed the conventional 
alginate SLG20 encapsulation in achieving insulin independence of diabetic mice. We 
chose 500 islet equivalents (IEq) from rat, and transplanted the devices to s.c. site of 
streptozotocin (STZ)-induced C57BL/6 diabetic mice. Notably, 500 IEq rat islets 
encapsulated by Alginate SLG20 have been reported to achieve at least ~20 days 
insulin independence at i.p. site. Here we found that Alginate SLG20 hydrogel/islet 
started to fail at ~10 days after s.c. transplantation in lowering blood glucose of 
diabetic mice (therapeutic level is 200 mg/ml) (Figure 3-10(a)). Meanwhile, 
zwitterionic PCBAA gel/islet was found to sustain the diabetes reversal during the 
entire 80 days of implantation period (Figure 3-10(b)). When PCBAA hydrogel/islet 
was retrieved on day 83, the blood glucose immediately went back to the 
pre-treatment level. Live and dead staining (green-fluorescent calcein-AM (live)/ 
red-fluorescent ethidium homodimer-1 (dead)) indicated that the explanted islets 




supreme capability to sustain islet survival and glucose response was due to the 
great blood vessel formation and tissue integration of PCBAA hydrogel. 
3.3.5 Implanted zwitterionic hydrogel had an unusual anti-inflammatory effect on 
local surrounding tissues. 
Among conventional biomaterials for implantable applications, high mannuronate 
(M) alginate has been identified to be able to promote blood vessel formation to 
certain extent, and has been used to encapsulate islets and demonstrated control of 
fasted diabetic non-human primate blood glucose for half a year136-137. However, the 
application of high-M alginate hydrogel was hindered due to the pro-inflammatory 
reaction produced by the material, with monocytes that produced high level of IL-1 
TNF-α and IL-6 which endangered the long-term survival of the islet138-139. Here we 
evaluated the potential inflammatory response of zwitterionic hydrogel materials 
together with control materials including high M alginate (Alginate SLM100, low 
endotoxin, from FMC Biopolymer). One month after s.c. implantation of these 
material disks in healthy mice, the materials with surrounding tissues were 
explanted and subjected to immunofluorescence histological study. Macrophages in 
the vicinity of the implant and their expressed pro-inflammatory (TNF-α, IL-1β, IL-12, 
iNOs) and anti-inflammatory cytokines (IL-10, TGF-β1, Arg-1, MMR) were triple 
labeled (Figure 3-11(a)). Zwitterionic PCBAA stimulate significantly less inflammatory 
cytokines, particularly compared with Alginate SLM100, PEGDA 10K, and PHEMA 
(p<0.0001), and drastically more anti-inflammatory factors, i.e., IL-10, compared 




accessibility plus the unusual anti-inflammatory capability, zwitterionic PCBAA 
hydrogel is expected to outperform most current biomaterials, including the highly 
promising high M alginate, in boosting the outcome of current implantable devices. 
In our islet encapsulation and s.c. transplantation test, we indeed observed that 
Alginate SLM100/ islet implant failed to control blood glucose starting at day ~10, 
while zwitterionic PCBAA/islet continuously reversing diabetes through the entire 80 
days of implantation (Figure 3-12). 
3.4 Discussion 
Our body evolved a vasculature systems with high density of blood vessels to 
enable sufficient exchange of oxygen, nutrition and metabolic waste of every single 
cell. An implantable device, ideally, requires a similar level of blood accessibility to 
sustain long-term therapeutic or monitoring function. However, most biomaterials 
could not evade foreign body attack and were unable to support blood vessel 
formation, no matter they are polymers, metals, or ceramics140-143. Our study for the 
first time showed that (1) zwitterionic hydrogel material supports the growth of new 
blood vessels to the same density level as naturally healed wound and healthy tissue, 
and maintains such natural density of vasculature for a long term. It is particularly 
noted that there is no sign of uncontrolled angiogenesis near to the zwitterionic 
hydrogel surface; this, however, is frequently observed with tumor vasculature, and 
when growth factors were overly delivered at the implantation site144-145. We further 
found that (2) the newly formed vessels were highly perfused with function, which 




hydrogel, and were discovered to stay very close to the PCBAA hydrogel surface and 
grow into the holes or the narrow space between two PCBAA hydrogels. By 
measuring how close these new functional vessels were to the zwitterionic surface in 
the cases of hydrogel disks, holes, and interspaces, it was found that the nearest 
blood vessels were typically within a perpendicular distance of 20 μm from the 
hydrogel surface. This indicated that the zwitterionic implants could be potentially 
highly accessible by the blood with one or a few cell layers in between. We further 
verified that (3) zwitterionic hydrogel implants are highly blood accessible, as 
indicated by the efficient accumulation of Evans blue dye on the hydrogel device, 
even after 5 months of implantation. It is worth noting that most of the current 
studies on blood vasculature around biomaterials focused mostly on blood vessel 
morphologies. Our work provided insights on the function of the newly formed 
vasculature and the blood accessibility of the implants. With natural tissue-like 
vasculature and superior blood accessibility, the zwitterionic hydrogel is expected to 
be a promising platform to improve long-term implantable device outcome (such as 
being the coating or surface materials for implantable devices).  
Our implantation study was exclusively performed on the subcutaneous (s.c.) site 
for two reasons. First, this location is ideal for many commonly found implantable 
devices such as vascular access devices, contraceptive devices, blood glucose sensor, 
cell delivery devices, cardioverter defibrillator: S.c. site is the most welcomed 
implantation site for the patience. The surgery could be easily performed in a local 




it will be easily retrieved and replaced to elongate the therapeutic function period. 
Second, s.c. site is known for poor vascularization, and is known to have less blood 
accessibility comparing to intraperitoneal (i.p.) or other sites. We showed 
remarkable neovascularization promotion and blood accessibility at this challenging 
site with zwitterionic hydrogel implants. This effectively addresses the current 
challenge preventing s.c. implant from achieving long-term device outcome, and also 
implies that zwitterionic hydrogel implants can perform as efficiently at other 
implantation sites. 
To highlight the capability of the zwitterionic hydrogel in improving implantable 
device outcome, we studied zwitterionic hydrogel as a novel material for islet 
encapsulation and transplantation. Islet Encapsulation by biomaterials is a potential 
solution to treat Type 1 Diabetes with insulin independence free of 
immunosuppressant146-148. Encapsulated islets will be protected by the polymers 
hydrogels from the attack of the body immune system and are shown to long term 
manage blood glucose. Nevertheless, there was few clinically relevant product of 
islet encapsulation even with over decades of research149. The crucial point in the 
successful islet transplantation is to sustain function and survival of the transplanted 
islets for a long term. Current biomaterials including hollow fiber, natural polymers 
such as agarose and alginate, and synthetic PEG have been extensively used as islet 
encapsulation materials150-152. These materials, however, resulted in poor blood 
accessibility after transplantation, which hindered the survival of islets because the 




prevents the implant from achieving desired long-term therapeutic function153-155. 
Here we observed that with superior blood accessibility, islets encapsulated by 
zwitterionic hydrogel achieved greatly improved therapeutic outcomes. In the s.c. 
site, zwitterionic PCBAA hydrogel/islet was able to correct diabetes during the entire 
80 days of implantation period, while both Alginate SLG20 gel/islet and SLM100 
gel/islet, two state-of-the-art technology, failed to lower blood glucose starting at 
less than 10 days (Figure 3-10, Figure 3-12).  
It is important to compare the zwitterionic PCBAA with Alginate SLM100 (high 
mannuronate (M)) and SLG20 (high guluronate (G)), two of the most popular 
alginate materials currently used for islet encapsulation, from both blood vessel 
promotion and anti-inflammatory standpoints. We consider inflammatory response 
in this comparison because most islet encapsulating materials are known for 
stimulating the production of cytotoxic cytokines upon implantation that penetrated 
to the encapsulated islets and cause islet death. Alginate SLM100 as s.c. implant with 
islet encapsulated has demonstrated the management of fasted blood glucose for 
half a year in diabetic primate studies. Our results show that SLM100 after 1-month 
s.c. implantation promoted new blood vessel growth to a density of 9.6±1.8 blood 
vessels per 0.2 mm2, but is still far below the 22.7±3.4 blood vessels per 0.2 mm2 for 
PCBAA that matched the normal tissue level (Figure 3-13). In addition, SLM100 (high 
M) was found to stimulate severe inflammatory response than SLG20156 (high G) 
(Figure 3-11), and high level of IL-6, IL-1 and TNF-α greatly endangered the long-term 




reaction compared with high-M alginates (Figure 3-11, well-consistent with the 
literature), and have been alternatively used for islet encapsulation. But SLG20 is 
even worse in promoting blood vessel growth (3.3±0.3 blood vessels per 0.2 mm2, 
Figure 3-1(c)). The advantage of zwitterionic PCBAA is obvious: it shows the 
strongest neovascularization promotion (as good as natural body system), the least 
inflammatory cytokine secretion, and the highest anti-inflammatory response. By 
overcoming both the blood vessel and inflammation challenges, zwitterionic PCBAA 
encapsulation technology has great potential to outperform the state-of-the-art islet 
encapsulation strategies in supporting long-term viability and function of 
transplanted islets. 
In summary, we report the first synthetic material ever known, namely 
zwitterionic hydrogel, promoting functional neovascularization as good as natural 
body system. This finding has a promising impact on current implantable devices in 
improving the device outcome. To highlight this implication, zwitterionic hydrogel 
was used to encapsulate islet cells for T1D treatment, with therapeutic outcome 











Figure 3-1 (a) Molecular structure of carboxybetaine acrylamide (CBAA) monomer 
and MBAA crosslinker which that used for making the PCBAA hydrogel. (b) 
represented histology images on blood vessel formation of hydrogel samples, 
healthy tissue and self-heal incision after one month transplantation. (c) The 
calculated density of blood vessels of all samples in (b). (d) Calculated blood vessel 
density for Long-term PCBAA hydrogel implantation in mice for up to half a year. All 
data are presented as mean of biological replicates (n=6) ± standard deviation. 
Statistical analysis: one-way ANOVA with Bonferroni multi-comparison. ***: p < 














Figure 3-2 Representative images of MECA-32 antibody staining of PCBAA 








Figure 3-3 (a) A represented image of MECA-32 antibody staining of B16F10 
melanoma tumor tissue. Scale bar = 50 μm. (b) Calculated blood vessel density of 
PCBAA hydrogel/tissue interface, normal tissue and tumor tissue, based on MECA-32 
staining results. All data are presented as mean of biological replicates (n=6) ± 
standard deviation. Statistical analysis: one-way ANOVA with Bonferroni 






Figure 3-4 (a) Illustration of green dye injection experiment. The mice with 
implanted samples receive tail vein injection of FITC-dextran in PBS solution. The 
samples and surrounding tissue were retrieved for imaging. (b) Represented images 
of FITC-dextran stained blood vessels for all hydrogel samples under fluorescence 
microscope. Scale bar = 50 μm. (c) images showing blood vessels grown into the hole 
in the center of a hydrogel disk and narrow space between two hydrogel disks. Scale 
bar = 400 μm. (d) Schematic representation of the two approaches in (c). (e) Blood 
vessels near to PCBAA hydrogel implants were perfused with green FITC-dextran. 
Gel/tissue interface was labeled by white dash lines. 20 μm away from the interface 









Figure 3-5 Blood vessel density for PCBAA, Alginate SLG20 and PEGDA 10K 
hydrogel/tissue interface, calculated from FITC-Dextran injection experiment. Data 
were presented as mean of biological replicates (n=3) ± standard deviation. 







Figure 3-6 Fluorescent image on tissues interfaced with PCBAA hydrogel disk 
containing a premade hole. The hydrogel disk was implanted for 2 months followed 






Figure 3-7 (a) dye accumulation of all explanted hydrogel samples (after different 
time points) under UV lamp after receiving i.v. injection of Evans Blue dye in PBS. (b) 
Fluorescent intensity quantification from (a). All data are presented as mean of 
biological replicates ± standard deviation (n=4, (n=3 for PCBAA at 5 months)). 







Figure 3-8 Evans Blue dye accumulation on Alginate SLG20, PEGDA 10K and PCBAA 





Figure 3-9. The first line exhibited the islets morphology in different materials after 
30 days’ implantation in normal healthy mice. The second line showed the 
corresponding glucose response capability of islets in different materials after 30 
days’ implantation. All data are presented as mean of biological replicates (n=6) ± 
standard deviation. Statistical analysis: one-way ANOVA with Bonferroni 






Figure 3-10 (a) Therapeutic curve of PCBAA hydrogel and Alginate SLG20 hydrogel 
devices with 500 IEq rat islets encapsulated. Live (green) and Dead (red) staining was 
performed at the end point as indicated. (b) The fraction of cured diabetic mice after 
being transplanted (non-fasted blood glucose level < 200 mg/dl). All data are 
presented as mean of animal replicates (n=6) ± standard deviation. Statistical 










Figure 3-11 (a) Macrophages in the vicinity of different material implants (within 
~100 μm from the tissue/hydrogel interface) were analyzed after 1-month 
implantation. Representative immunofluorescence histological images were 
obtained through triple staining with the indicated markers. (b) Percentage of 
macrophages expressing pro-inflammatory (interleukin 10 (IL-10), transforming 
growth factor beta 1 (TGF-β1), arginase-1 (Arg-1) and macrophage mannose 
receptor (MMR)) and anti-inflammatory (tumor necrosis factor alpha (TNF- α), 
interleukin 1 beta (IL-1 β), interleukin 12 (IL-12) and Inducible nitric oxide synthase 
(iNOs)) biomarkers. All data were showed as mean of biological replicates (n=10) ± 
SEM. Statistical analysis: one-way ANOVA with Bonferroni multi-comparison. *: p < 






















Figure 3-12 (a) Therapeutic curve of PCBAA hydrogel, alginate SLG20 gel and alginate 
SLM100 gel devices with 500 IEq rat islets encapsulated. (b) The fraction of cured 
diabetic mice after being transplanted (non-fasted blood glucose level < 200 mg/dl). 
All data were showed as mean of animal replicates (n=6; for SLM100, n=4) ± 













Figure 3-13 (a) Representative image of MECA-32 antibody staining of Alginate 
SLM100 hydrogel/tissue interface. Scale bar = 50 μm. (b) Calculated blood vessel 
density of PCBAA hydrogel/tissue interface and alginate SLM hydrogel/tissue 
interface, based on MECA-32 staining results. Data were showed as mean of 
biological replicates (n=3) ± standard deviation. Statistical analysis: unpaired, 

















CHAPTER 4. A MACRO-CROSSLINKER FOR DURABLE ANTI-FOULING COATING 
4.1 Introduction 
Zwitterionic polymer coatings were effective to solve Biofouling problem that 
causes implantable device failure and unwanted microorganism attachment. 
However, zwitterionic polymer coating is usually fragile with only short-term function 
since these super-hydrophilic polymers tends to dissolve in water. In this chapter, we 
described and synthesized a novel zwitterionic macro-crosslinker to overcome the 
vulnerability of zwitterionic coating. The macro-crosslinker coating was highly 
crosslinked over the whole surface with much greater thickness than common 
polymer brush coating and stayed in presence on polyurethane (PU) surface to 
maintain function even after long term treatment in flowing phosphate buffered 
saline (PBS). The macro-crosslinker coating enabled the application of zwitterionic 
polymer in durable anti-biofouling coating for long term function. 
  For many applications involving surface exposure to biomolecule and 
microorganism, biofouling is a serious problem that causes implantable device 
failure157-158 and unwanted microorganism attachment159-160. Recently, surface 
modification with non-fouling polymer has been utilized to overcome the biofouling 
problem161-162. Encouraging results had been obtained in various applications on 
different traditional substrates such as anti-thrombosis polyurethane catheters and 
coatings on metal ship hull to resist marine fouling163 by using non-fouling 
zwitterionic polymers. Zwitterionic polymer coatings are super-hydrophilic and 




bacteria adhesion164. Many methods have been involved in fabricating zwitterionic 
coatings165. Nevertheless, the resulting zwitterionic polymer coatings are typically 
unstable with only short-term function, regardless of how they are immobilized on 
the surface166. Unlike hydrophobic polymer coatings, super-hydrophilic polymer 
coatings drastically tend to dissolve into water environment. This leads to gradual 
exposure of the coated surface over time167, and hinders the use of zwitterionic 
coating in applications that require long term durability46. Despite significant efforts 
in this field168, it remains a challenge to fabricate durable non-fouling coating using 
super-hydrophilic zwitterionic polymers. 
  In this work, we synthesized zwitterionic macro-crosslinker to overcome the 
vulnerability and challenge in developing durable anti-fouling coatings. Double bonds 
were introduced to high molecular weight (Mw) zwitterionic polymer backbone, 
which was then crosslinked on polyurethane substrate by graft-from method. 
Different from single polymer chain which was easily torn away from the surface, the 
macro-crosslinker coating was highly crosslinked over the whole surface with 
significantly increased thickness and remained on polyurethane (PU) surface to 
sustain non-fouling function even after long term shearing in flowing phosphate 
buffered saline (PBS). Synthesis of the zwitterionic macro-crosslinker was verified by 
Nuclear Magnetic Resonance (NMR) and coating thickness was characterized by 
surface ellipsometry and scanning electron microscope (SEM) visualization. Contact 
angle, protein absorption and bacteria adhesion were utilized to examine the 




macro-crosslinker coating was much more durable than common brush polymer 
coating and conventional small molecule crosslinking strategy, indicating its potential 
for durable (or long-term) anti-fouling applications. 
4.2 Materials and methods 
4.2.1 Materials  
2-Aminoethyl methacrylate hydro-chloride (NH2-MA monomer, 90%), Tert-Butyl 
bromoacetate (98%), 2-(Dimethylamino) ethyl mathacrylate (DMA 98%), 
N,N-Methylenebis(acrylamide) (MBAA, 99%), Anhydrous DMF, Anhydrous Acetone 
(99.99%) and Anhydrous methanol were purchased from Sigma-Aldrich, St. Louis, 
MO. Triethylamine (TEA, 99%), trifluoroacetic acid (TFA, 99.9%) and Ethyl Ether 
anhydrous (99.9%) were obtained from Fisher Chemical. Co. Deuterium Oxide (D2O 
99.9%) and Dimethyl sulfoxide-D6 (D-DMSO, 99.9%) were obtained from Cambridge 
Isotope Laboratories, Inc. USA. 
4.2.2 Synthesis of PCBMA-tBu monomer 
The synthesis procedure was as reported previously4. Briefly 5 g 
2-Dimethylamino-ethyl methacrylate and 8.68 g tert-butyl bromoacetate were 
reacted in 20 ml acetonitrile for 24 h at 50 oC under N2 protection. Upon addition of 
250 ml ethyl ether to the reaction mixture, the white crystals were isolated and dried. 
The resulting CBMA-tBu monomers were immediately stored in a desiccator at -20 oC 
(yield 96%) 
4.2.3 Synthesis of PCBMA macro-crosslinker 




2-Hydroxy-4-(2-hydroxyethoxy)-2-methylpropiophenone (photo-initiator, I-2959) in 
anhydrous DMF. The CBMA-tBu ester monomer was first copolymerized with 
2-Aminoethyl methacrylate hydro-chloride (NH2MA monomer) at different molar 
ratio (10:1, 30:1 and 50:1) in the polymerization solvent (35% by weight) under UV 
for 10 min and the resulting polymer A was precipitated in anhydrous acetone. 
Unreacted monomer was washed away by re-dissolving the product in DMF and 
precipitated in acetone for additional two times (polymer yield: 56%). The purified 
copolymer A was then reacted with acryloyl chloride (3 times of the amount of NH2 
function group) in presence of triethylamine in anhydrous DMF (10% by weight) for 5 
h at room temperature followed by precipitation in anhydrous ethyl ether and 
vacuum dry (polymer B, yield: 87%). Lastly, copolymer B was stirred in trifluoroacetic 
acid (20% by weight) to remove tBul ester protection and neutralized using 
triethylamine (TEA) to pH=7 in anhydrous methanol on ice bath. The obtained 
zwitterionic macro-crosslinker C was precipitated in ethyl ether and dried in vacuum 
(macro-crosslinker C yield: 91%; overall yield: 44%).  
4.2.4 Characterization  
The molecular weight of the macro-crosslinker and surface initiated polymer 
(obtained by ultrasonic treatment after coating) were determined by gel permeation 
chromatography (GPC) on a Waters Alliance 2695 Separations Module equipped with 
a Waters Ultrahydrogel Linear column and a Waters 2414 reflex detector. The mobile 
phase was PBS buffer solution at a flow rate of 0.7 ml/min at 35 oC. Poly(ethylene 




were examine using a Varian Mercury-400 MHz NMR. In Figure 2 of the main text, 
the product A and B were dissolved in D-DMSO and product C was dissolved in D2O. 
The coating thickness was characterized by surface ellisometry and averaged from 
three measurements at different surface site (α-SETM, J.A. Woollam Co., Inc.). 
4.2.5 Protein absorption 
  To measure the fibrinogen (Fg, Sigma-Aldrich) adsorption on PCBMA 
macrocrosslinker coating, coated surface (either by PCBMA brush or PCBMA 
macrocrosslinker) and bare PU surface were incubated with 1mg/ml Fg in a well plate 
for 10 minutes at room temperature, followed by 5 washes with PBS buffer. Samples 
were then incubated with 1 mg/ml bovine serum albumin solution for 10 minutes at 
room temperature with 5 times wash again with PBS buffer. The tested surface were 
then removed from the fifth PBS wash and transferred to new wells. They were next 
incubated with a 1:200-dilution of horseradish peroxidase (HRP)-conjugated 
anti-fibrinogen in PBS for 10 minutes, followed by another 5 washes with the same 
buffer. After the fifth wash, the tested surfaces were transfer to new wells and 
SIGMAFAST OPD was added to each well at 30-second intervals. The surfaces were 
incubated in the OPD solution for 30 minutes away from light. The supernatant was 
removed from each test well, transferred to a cuvette, and its absorbance at 490 nm 
was measured. All samples were measured in triplicate. 
4.2.6 Bacteria adhesion and SEM image 
After bacteria adhesion on PU, the surface will be immersed in the fix solution of 




surface was then dehydrate in a gradient ethanol series and dried in vacuum. Before 
imaging, the surface sample was coated with nano-gold using a SEEVac Conductive IV 
sputter coater. The bacteria were imaged using a JSM - 6510LV SEM at 5 um 
magnification and bacteria adhesion density was calculated by counting the bacteria 
number per 900 um2. 
4.3 Results and discussions  
The synthesis of zwitterionic macro-crosslinker, based on polycarboxy betaine 
methacrylate (PCBMA), involves 3 steps of reaction and each step was monitored by 
1H-NMR (Figure 4-1). The CBMA-tBul ester monomer was first copolymerized with 
2-aminoethyl methacrylate hydro-chloride (NH2MA monomer) at different molar 
ratio (m:n=10:1, 30:1 and 50:1) in anhydrous dimethylformamide (DMF) using 
random free radical polymerization and the resulting polymer A was precipitated in 
anhydrous acetone. Unreacted monomer was washed away by re-dissolving the 
product in DMF and precipitated in acetone for additional two times. NMR spectrum 
for polymer A showed no peak between 5-6 ppm, indicating the complete removal of 
both unreacted CBMA-tBu and NH2MA monomers. An emerging peak (b at 7 ppm) 
implied successful incorporation of NH2MA unit into the PCBMA-tBu ester polymer 
backbone. The purified copolymer A was then reacted with acryloyl chloride in 
presence of triethylamine in anhydrous DMF followed by precipitation in anhydrous 
ethyl ether and vacuum dry. The obtained copolymer B had its NMR peak b 
completely replaced by peak c (5-6 ppm, for acryloyl chloride) with an undetectable 




were completely reacted with acryloyl chloride. Lastly, copolymer B was treated by 
trifluoroacetic acid (TFA) to remove tBu ester protection and neutralized using 
triethylamine (TEA) to pH=7 in anhydrous methanol on ice bath. The obtained 
zwitterionic macro-crosslinker C was precipitated in ethyl ether and dried in vacuum 
(overall yield: 44%). Complete removal of tBu ester groups was confirmed by the 
disappearance of peak a (1.2 ppm) for tBu ester shown in copolymer A and B (spectra 
for different double bond ratio see Figure 4-2). Free radical polymerization was 
chosen here since there was no any toxic catalyst involving and small molecule could 
be easily removed, which was crucial for potential in vivo application such as coatings 
for catheters. 
The coating on hydrophobic PU substrate was produced by a surface graft-from 
redox polymerization method which was reported previously169. We chose graft-from 
method because it was able to induce densely distributed polymer chain that was 
proved to effectively cover the whole surface in various shapes and inner side of 
tubes170. Briefly, our model substrates, PU coupons, were immersed in a 1% solution 
of tert-butylperoxy 2-ethylhexyl carbonate (TBEC) in isopropyl alcohol (IPA) for 2 
hours at room temperature. After a few times of gentle wash with ethanol, the 
coupons were transferred to a polymerization solution of 10% (weight ratio) PCBMA 
macro-crosslinker containing 5 mM Fe(II) gluconate at 40°C for 12 h. In our control 
study, 10% CBMA monomer, or 10% CBMA monomer with commonly used small 
molecule crosslinker, N,N-Methylenebis(acrylamide) (MBAA), were used in the 




respectively. Unreacted TBEC was removed by repeated gentle rinse with IPA. The 
coupons with surface coatings were dried in vacuum before test. 
The coating thickness was characterized by surface ellipsometry using the bare PU 
surface as the control (Figure 4-3). Immediate after the coating reaction, the 
macro-crosslinker coating showed much greater thickness (>300 nm) than the 
polymer brush coating (11±1.3 nm), and the brush coating with MBAA crosslinker 
(11.5±1.6 nm) at the same crosslinking density as macro-crosslinker (MBAA/CBMA 
monomer ratio = double bonds unit/PCBMA unit). Under SEM, the coating for 
polymer brush and the one crosslinked with MBAA could hardly tell, but the thick 
coating of macro-crosslinker could be clearly visualized. Gel permeation 
chromatography (GPC) characterization showed that the macro-crosslinker had an 
average molecular of 174 KDa, which was much larger than the surface initiated 
polymer brush (4.5 KDa). There were several reasons explaining the resulting low 
MW of polymer brush. 1) There was steric hindrance between polymer brush chains 
preventing the chain from growing larger171. 2) Surface redox polymerization was not 
effective to produce high MW polymer since only monomer near the surface 
participates the chain growth. 3) The presence of 5 mM Fe(II) gluconate, which was 
the reducing agent to induce free radical generation on hydrogen peroxide of TBEC, 
greatly decreased the solubility of zwitterionic monomer (maximum 18% by weight), 
preventing further increasing the monomer concentration as a way to increase the 
Mw of resulting polymer. Coating thickness from different methods was further 




thickness (from 10±1.2 nm to 2.1±0.2 nm) while macro-crosslinker coating was 
almost intact (4 % thickness loss). 
The durability of the surface coating made through different methods was further 
examined by measuring water contact angles after different days of incubation in 
water (Figure 4-4). Without any zwitterionic polymer coating, the bare PU surface 
was hydrophobic showing a typically water contact angle around 70°. After the 
coating through all tested methods, the contact angle decreased to around 8°, 
indicating the efficient introduction of super-hydrophilic zwitterionic polymers onto 
the PU surface. Nevertheless, as days went by, the contact angles for polymer brush 
coating and polymer brush coating crosslinked by MBAA gradually increased and 
reached the original contact angle of 70° (for bare PU) after two weeks. This suggests 
that coatings were almost completely lost upon two weeks incubation in water. 
Addition of small molecule crosslinker MBAA to mimic the same theoretical 
crosslinking density of macro-crosslinker only led to negligible improvement in 
durability. The contact angle for the macro-crosslinker coating, by contrast, remained 
unchanged after one week and increased to 19° after two weeks, indicating greater 
durability of this particular coating. 
Zwitterionic material coatings were known for great non-fouling property that 
resists non-specific protein binding and microorganism attachment, and can be 
potentially applied on blood-contact biomedical devices, e.g., catheters, to resist 
thrombosis and ship hulls to resist marine fouling. In these circumstances, coatings 




required more durable coating technology to maintain long term anti-fouling 
performance172. To test the durable function of the zwitterionic macro-crosslinking 
coating under shear stress, the coating was exposed to PBS solution under 1500 rpm 
stirring for one week and taken out for functional test. Human fibrinogen was utilized 
for protein binding test and results before and after one week of flow condition were 
compared (Figure 4-5). It was found that all coating methods were able to produce a 
freshly-made coating that resists fibrinogen binding. However, after one week 
exposure to flow condition, polymer brush coating and brush coating with MBAA 
crosslinking lost anti-fouling function with protein binding returning to the level of 
bare PU surface. The macro-crosslinker coating showed almost the same low level of 
protein binding before and after the flow treatment, suggesting its superior 
durability under shear stress condition. We further conducted bacterial attachment 
assay as additional functional test for the coatings using E. coli. as a model bacterium. 
After flow condition treatment in PBS, the coatings were transferred to high 
concentration bacteria suspension (1.12*109 cell/ml) for 0.5 h, followed by repeated 
washes with sterile PBS, fixation, dehydration and vacuum drying. The bacteria 
attached on the coating surface were visualized under SEM and their density was 
calculated (Figure 4-5). Similar results were obtained to the protein adsorption test. 
After one week flow condition, the macro-crosslinker coating had almost zero 
bacteria adhesion, but coating of polymer brush and the brush with MBAA 
crosslinking showed bacterial adhesion as worse as bare PU surface. 




hydrophobic substrate with non-fouling property. However, these coatings were 
usually vulnerable with only short-term function, since super-hydrophilic polymer 
chains would be easily washed away by aqueous environment. It is obvious that 
crosslinking individual polymer brush chains could help stabilize the overall 
coatings173. In a crosslinked surface network, if one polymer chain tended to be torn 
away from the surface, its neighbouring covalently linked polymers would retain it 
from dissolving into water environment. Our results showed that different 
crosslinking strategies had different levels of stabilizing effect on the coatings (Figure 
4-6). What we found was small molecule crosslinker MBAA did not improve stability 
of polymer brush, and the resulting crosslinked coatings was far less durable than 
macro-crosslinker coatings. This could be potentially explained by 1) low local 
concentration of MBAA (at the kept CBMA/MBAA ratio) led to relatively inefficient 
crosslinking and 2) the monomer concentration could not be further increased in 
presence of Fe(II) gluconate. We did observed that the small crosslinker MBAA 
strategy was inefficient to further increase the coating thickness (11.5±1.6 nm) 
compared with macro-crosslinker strategy (>300 nm). A thicker coating has generally 
shown enhanced durability174.  
  In summary, we demonstrated the synthesis of novel zwitterionic 
macro-crosslinker enabling the formation of durable non-fouling coating on common 
hydrophobic plastic substrate, PU. Coating formed using the macro-crosslinker 
exhibited much greater thickness and durability compared to common polymer 




incubation in water, macro-crosslinker coating was able to sustain hydrophilicity for 
more than two weeks. Even under shear flow condition, the macro-crosslinker 
coating was able to retain its non-fouling property to resist protein and bacteria 
adsorption after one week treatment, while all other methods failed. The durable 
zwitterionic macro-crosslinker coating can be potentially applied on blood-contact 






















































Figure 4-2 1H-NMR of PCBMA macro-crssolinker with different double bond density 

















































Figure 4-4 (a) Time course contact angles for coating surfaces made from different 



























Figure 4-5 (a) Protein binding test on coatings obtained from different methods 
before and after one week exposure in flowing PBS, and E. coli adhesion test on 
coatings obtained from (b) bare PU, (c) PCBMA brush coating, (d) PCBMA+MBAA 

























CHAPTER 5. SUPER-DURABLE COATING FABRICATED FROM A DOUBLE-SIDED TAPE 
WITH LONG TERM “ZERO” BACTERIAL ADHESION 
5.1 Introduction  
In this Chapter, we will describe a novel durable zwitterionic polymers coating that 
for the first-time potential addresses the tough biofilm issue. The novel coating can 
be applied on many common substrates as easy as a double-sided tape. Simply apply 
superglue on a given surface, apply the coating tape we developed on top, remove 
the tape liner, and then the coating is obtained. The novel coating shows the 
toughness and durability that have not yet been achieved by any reported one. Most 
remarkably, this coating achieved unprecedented capability to resist biofilm. 
State-of-the-art anti-fouling coatings started to accumulate bacteria after just a few 
hours of contact and would be covered with dense biofilm usually in less than 7 days. 
Our coating was able to achieve almost “zero” bacteria adhesion even after 
one-month continuous contact with high concentration bacteria. Our coating 
technology is convenient to apply and can promisingly solve the biofilm threat, 
which deteriorates public health and impedes the function of most biomedical 
devices. 
There is no coating technology currently available that can prevent the notorious 
biofilm formation issue175-176, which induces infections177-179 and impede device 
function117, 180. The state-of-the-art anti-biofilm coatings are complex to fabricate 
and poor in performance due to instability in working environment47. They usually 
started to accumulate bacteria after immediate contact and would be covered with 




to fully address this tough biofilm issue by developing an easily-applied 
super-antifouling coating. Our coating was able to achieve almost “zero” bacteria 
adhesion even after one-month continuous contact with high concentration 
bacteria. 
Our novel Durable and Ultra-Robust Antifouling Zwitterionic (DURA-Z) coating 
combined the use of a zwitterionic hydrogel tape (a double-sided tape) and 
commercial superglue, and can be easily fabricated and universally applied on 
common substrates. Super-hydrophilic zwitterionic polymer materials are known for 
their superior antifouling properties182. But they, like common hydrophilic coatings, 
drastically tend to dissolve in the aqueous environment resulting in poor coating 
durability166, 168. The vulnerability to mechanical damages further prevents these 
hydrophilic coatings from being practically applied183. Superglue based on ethyl 
cyanoacrylate is one of the strongest linkages ever known for daily bonding projects, 
and is known to only glue hydrophobic materials such as metal, plastic or wood. It 
cannot stably bind to hydrophilic ones, e.g., glass slide which has a water contact 
angle of ~28°. Against this conventional wisdom, here we were able to immobilize a 
super-hydrophilic DURA-Z gel network (water contact angle < 2°) with the 
hydrophobic superglue, through a unique interpenetration mechanism. The obtained 
DURA-Z coating was super-hydrophilic and retained anti-fouling property after 
various long-term durability tests in aqueous environments by incubating (90 days), 
shearing (50 days) and flushing (30 days), as well as mechanical damage tests by 




abrasion test is more than 150 times higher than other similar tests for coating 
stability184. Remarkably, DURA-Z coating was able to achieve almost “zero” bacteria 
adhesion for at least one month when continuously incubated with highly 
concentrated bacteria (> 109 cells per ml) in culture media at both dynamic and static 
conditions. This remarkable anti-biofilm performance has rarely been achieved. 
DURA-Z coating can be easily removed from the substrate and re-applied, which 
further extends the applicability of this coating strategy. 
5.2 Materials and methods 
5.2.1 Materials 
Polyurethane coupons were purchased from BioSurface Technology. Stainless 
steel strips were purchased from McMASTER-CARR. All solvents and chemicals were 
purchased from Sigma-Aldrich and were used as received. 
5.2.2 Fabrication of DURA-Z tapes. 
DURA-Z tapes were fabricated by in-situ forming of a thin layer of PCBAA hydrogel 
on commercially available polypropylene liner. Briefly, 5 mg 
2-Hydroxy-4’-(2-hydroxyethoxy)-2-methylpropiophenone (I-2959) initiator and 30 
mg N,N’-Methylenebis(acrylamide) (MBAA) crosslinker were dissolved in 10 ml DI 
water. 300 mg CBAA monomer was then dissolved in 300 µl initiator/crosslinker 
solution to prepare a pre-gel solution, which was transferred to between two 
polypropylene liners adhered to glass slides separated with a Teflon spacer (1 mm in 
thickness). UV was applied for a few minutes to crosslink the PCBAA hydrogel. 




from glass slides. 
5.2.3 Fabrication of DURA-Z coating. 
The polyurethane (PU), stainless steel, glass and wood substrates were cleaned 
with alcohol and dried in air (wood and metal were pre-treated by sandpaper to 
obtain rough surfaces, and glass was pre-coated with a thin layer of EVO-stik glue). 
Then one drop of cyanoacrylate superglue (ACE Hardware Corp.) was applied onto 
the dried substrate, followed by pressing the DURA-Z tape (hydrogel layer facing 
down) onto the superglue for a few seconds. One hour was then allowed to 
completely solidify the superglue. The liner on top of the hydrogel was removed, and 
the glued coating was transferred to DI water for equilibrium. 20 mins later, the 
DURA-Z coating was polished either by a small shovel or tweezer, leaving the surface 
with a thin layer of coating. 
5.2.4 Scanning Electron Microscope (SEM) imaging. 
samples were dried in vacuum and then coated with nano-gold using an SEEVac 
Conductive IV sputter coater before imaged by a JSM - 6510LV SEM. For sectional 
imaging, all tested coupons (bare PU, superglue coated and DURA-Z coated 
substrates) were vertically cut into half using a sharp scalpel to expose the 
cross-section. 
5.2.5 Atomic-force Microscopy (AFM) imaging 
AFM imaging of the bare PU, superglue coated and DURA-Z coated substrates was 
conducted on a Dimension 3100 AFM from VEECO. All samples were vacuum dried 




through the tapping mode using silicon probes (VEECO) with a nominal frequency of 
150 kHz. The AFM images were analyzed using Nanoscope software version 5.12. 
5.2.6 Infra-red (IR) characterization 
Bare PU, superglue coated and DURA-Z coated substrates were vacuum dried 
before testing. PCBAA hydrogel was freeze-dried before testing. All samples‘ surfaces 
were characterized on a NICOLET 6700 IR (Thermo Electron Corporation) equipped 
with an attenuated total reflectance (ATR) accessory. 
5.2.7 Contact angle 
The water contact angle on bare PU, superglue coated and DURA-Z coated 
substrates was conducted using a KSV contact angle instrument equipped with a 
camera at room temperature and ambient humidity. 2 μl of water was dropped on 
different surfaces and water contact angle was calculated using by the CAM2008 
software. 
5.2.8 Durability tests in aqueous environment 
PBS shearing was created on a stirring plate by a 5-cm stirring bar at 1500 rpm in a 
beaker (D = 10 cm). The tested samples were firmly clamped and positioned at the 
inner wall of the beaker, and subjected to the continuous shear stress of 202 G. Body 
temperature (37 °C) was controlled by the stirring plate and DI water was added to 
compensate the evaporation every day to maintain standard PBS concentration. In 
water flushing test, water was cycled by an electric pump with a flow rate of 42.8 





5.2.9 Mechanical damage tests 
For the knife-scratch test, DURA-Z coating on PU coupon was randomly cut by a 
sharp scalpel. The abrasion test was conducted on an INSTRON compressor 
equipped with a precise loading detector. Sandpapers (Gator waterproof sanding 
400 grit) were fixed on both sides of the compressor and the pressure was calculated 
by the loading divided by the area of PU coupon. One cycle of abrasion contains 
pushing and pulling the coupon for 1-cm displacement back and forth under a given 
pressure. The samples were subjected to 20 cycles of abrasion. Water wettability 
and protein adsorption tests were conducted on the samples before and after the 
mechanical damage challenge. 
5.2.10 Protein absorption test (ELISA) 
Human fibrinogen (Fg, Sigma-Aldrich) adsorption on a variety of substrates (bare 
substrates, superglue coated and DURA-Z coated substrates) was measured using 
ELISA method. All samples were incubated with 1mg/ml Fg for 10 minutes at room 
temperature, followed by 5 washes with PBS buffer. They were then incubated with 
1 mg/ml bovine serum albumin solution for 10 minutes at room temperature with 5 
washes again with PBS buffer. The samples were removed from the fifth PBS wash 
and transferred to new wells. They were next incubated with a 1:200-dilution of 
horseradish peroxidase (HRP)-conjugated anti-fibrinogen (USBiological, Life Sicences) 
in PBS for 10 minutes, followed by another 5 washes with PBS buffer. After the fifth 
wash, the samples were transferred to new wells and SIGMAFAST OPD 




30 minutes in the dark. The supernatant was removed from each test well, 
transferred to a 96-well plate, and its absorbance at 490 nm was measured using a 
UV-VIS spectrometer (Thermo Scientific Multiscan Go). All samples were measured 
in triplicate. 
5.2.11 Biofilm resistance of DURA-Z coating. 
E. coli bacteria were cultured for 24 h at 37 °C on Luria-Bertani (LB) agar plates. 
One colony was picked and cultured in 20 mL of LB broth medium overnight at 37 °C 
on a shaker (Standard Analog Shaker, VWR) at 200 rpm. The resulting culture was 
used to inoculate a second culture in 50 mL of LB medium until an optical density 
(OD) of 0.8 at 600 nm was reached. The bacteria were collected by centrifugation at 
8,000 x g for 10 min at 4 °C, washed three times with sterile PBS (pH 7.4) and finally 
suspended in LB broth to get a final concentration of 1.05×109 cells per ml (OD = 1.31 
at 600 nm) for biofilm formation test. In the dynamic method, PU (stainless steel, 
wood, and glass) substrates, superglue coated substrates and DURA-Z coated 
substrates were placed in bacterial culture medium (LB Broth) containing highly 
concentrated bacteria (1.05×109 cells per ml) at 37 °C for 30 days under continuous 
shaking (300 rpm). The culture medium was gently refreshed every two days, and 
the bacterial density within the refreshed medium was kept at 1.05×109 cells per ml. 
In the static method, PU substrates, superglue coated substrates and DURA-Z coated 
substrates were stationarily placed in bacterial culture medium (LB Broth) containing 
highly concentrated bacteria (1.05×109 cells per ml) at 37 °C for 30 days. Bacteria 




medium was gently refreshed day by day, and the bacterial density within the 
refreshed medium was kept at 1.05×109 cells per ml. After long-term incubation, all 
substrates were rinsed with PBS for 30 mins (samples tested in the static method 
were also imaged without rinsing). After the challenging periods, the substrates were 
then immersed in the fix solution of 2.5% glutaraldehyde, 2% paraformaldehyde in 
0.1 M sodium phosphate buffer and were then dehydrated in a gradient ethanol 
series and dried in vacuum before SEM imaging. Adhered bacteria density was 
counted by averaging 6 randomly selected areas (100 µm2 each). 
5.3 Results and discussion  
The formation of DURA-Z coating involves the combined use of a fabricated 
double-sided DURA-Z tape and superglue obtained from the hardware store. DURA-Z 
tape was prepared by the in-situ growing of a thin layer of zwitterionic 
poly-carboxybetaine acrylamide (PCBAA, 3-((3-acrylamidopropyl) 
-dimethylammonio)-propanoate) hydrogel on a commercial polypropylene (pp) liner 
(Figure 5-1(a)). The fabricated hydrogel tape was mechanically stronger than the 
pure zwitterionic PCBAA hydrogel and can withstand pulling, bending, wrenching 
and rolling up (Figure 5-1(b)). This ensures ease of storage, transport, and mounting 
of the DURA-Z tape on substrates to be coated. The fabricated DURA-Z tape can be 
directly mounted as a coating layer without further treatment.    
The DURA-Z coating can be glued on a variety of substrates through a simple 
procedure (Figure 5-1(c)). Briefly, a substrate was firstly cleaned, e.g., the 




of cyanoacrylate superglue was applied onto the dried substrate, followed by 
pressing the DURA-Z tape (hydrogel layer facing down) onto the superglue for a few 
seconds. One hour was allowed to completely solidify the superglue. The liner on top 
of the hydrogel was removed, and the glued coating was transferred to DI water for 
equilibrium. 20 mins later, the DURA-Z coating was polished either by a small shovel 
or tweezer, leaving the surface with a thin layer of coating. 
The resulting DURA-Z coating showed completely different morphology compared 
to PU substrate or cyanoacrylate superglue surface under Scanning Electron 
Microscope (SEM, Figure 5-2(a)), and Atomic-force Microscope (AFM, Figure 5-3). 
SEM images on coating cross-section provided structural details of a surface 
hydrogel layer and a hydrogel/glue interpenetrating layer (Figure 5-2(a)). The overall 
thickness of the coating (two layers) was measured to be 324±13 µm. The surface of 
the DURA-Z coating was characterized by Infrared (IR) spectroscopy and showed 
almost the same chemical composition as pure zwitterionic PCBAA hydrogel (Figure 
5-2(c)). This implied the surface of the DURA-Z coating had superior anti-fouling 
property as good as a zwitterionic hydrogel. Water contact angle (Figure 5-2(b)) 
indicated that DURA-Z coating was super-hydrophilic with great wettability (water 
drop spread out quickly), similar to pure PCBAA hydrogel surface. 
Super-hydrophilic polymer coatings were known to be unstable since polymers 
drastically tended to dissolve in water. Common hydrophilic coatings would fail 
within a few weeks in an aqueous environment. We incubated the DURA-Z coating in 




coating was almost unchanged, and anti-fouling property (tested by human 
fibrinogen binding followed by ELISA quantification of the absorbed protein) was 
retained at the same level as freshly-made coatings after the long-term incubation 
(Figure 5-4(a)). DURA-Z coating was further examined under various durability tests 
in the water condition, including (1) exposed to PBS buffer shearing (1500 rpm, 
202G) at room temperature for 50 days (Figure 5-4(b)), (2) exposed to PBS shearing 
(1500 rpm, 202G) at body temperature (37 °C) for 30 days (Figure 5-5(a)), and (3) 
subjected to continuous perpendicular water-flush at a flow rate of 42.8 ml/s for 30 
days (Figure 5-5(b)). These challenging conditions did not change the morphology of 
the DURA-Z coating, and the antifouling property of the coating was well retained, 
indicated by the unchanged, significantly lowered human fibrinogen absorption on 
the coating, compared with uncoated PU (Figure 5-5(a) and (b)).  
The DURA-Z coating was further subjected to mechanical damage tests. We used a 
sharp scalpel to randomly scratch the coating (Figure 5-5(d)). The coating retained its 
small water contact angle and great anti-fouling property (Figure 5-5(d)). We further 
examined the coating in an abrasion test, where a PU coupon with both sides coated 
with DURA-Z was placed between two stationary sandpapers (400 grit) and a 
pressure of 570 kPa was applied by a compressor (Figure 5-5(c)). The coupon was 
moved back and forth (displacement = 1 cm) for 20 circles and the coating was found 
to survive this abrasion test with great water wettability, and unchanged great 
anti-fouling property (Figure 5-5(c)). It should be noted that the 570 kPa pressure 




coating stability. In our sandpaper abrasion test, a PU coupon without DURA-Z 
coating applied cannot be moved by manpower under a pressure of 50 kPa. It 
appears that the slippery surface of DURA-Z coating contributes to its great 
capability to resist abrasion damage. 
Microorganism attachment on surfaces leads to biofilm formation that causes 
medical device failure, infection and marine fouling related fuel penalty. Hydrophilic 
polymer coatings, such as zwitterionic polymers, are non-toxic and environmentally 
friendly and have shown their effectiveness in resisting microorganism 
adhesion185-187. Nevertheless, due to the instability of hydrophilic polymers in an 
aqueous environment, these coatings were not able to maintain the resistance to 
microorganism adhesion for a longer period of time. Here we expect the 
ultra-durable and robust DURA-Z coating can greatly improve long-term 
microorganism resistance performance. To highlight this property, we utilized 
Escherichia coli (E. coli) as a model system to study the coating’s resistance to biofilm 
formation and quantified the bacterial adhesion by SEM. Our initial study has 
challenged the coating with dynamic bacterial culture condition. DURA-Z coated PU 
substrate was placed in bacterial culture medium (Luria-Bertani Broth) containing an 
extremely high number of bacteria (1.05×109 cells per ml) at 37 °C for 30 days under 
continuous shaking (300 rpm). The culture medium was gently refreshed every two 
days, and the bacterial density within the refreshed medium was kept at 1.05×109 
cells per ml. After 30 days, bacteria on the substrate surface were fixed, dehydrated, 




bacteria on the zwitterionic DURA-Z coating, while biofilm had developed on the 
bare PU substrate and the superglue coated surface (Figure 5-6 (a) and (b)).  
We further challenged the DURA-Z coating with one of the harshest condition, 
where high-density bacteria (1.05×109 cells per ml) were stationarily cultured with 
the substrate in LB broth at 37 °C, and allowed to settle on the substrate surface 
through gravity. The culture medium was gently refreshed day by day, and the 
bacterial density within the refreshed medium was maintained at 1.05×109 cells per 
ml. After 30 days, without any rinsing, only a small amount of bacteria was found to 
be scattered on DURA-Z coating (no biofilm forming) under SEM (Figure 5-7). With 
30 min of rinsing in PBS, these scattered bacteria were easily washed off from the 
DURA-Z coating (Figure 5-6(c) and (d)). By contrast, a biofilm (high-density bacteria 
adhered) formed on the bare PU substrate and superglue coated substrate, and 
remained to be firmly attached even after rinsing (Figure 5-6(c) and (d)). It should be 
noted that long-term biofilm resistance was highly desirable to reduce infection and 
extend medical device lifetime, but remained a challenge in the field188. We attribute 
the observed remarkable long-term biofilm resistance to the combined effect of 
ultra-low fouling property and ultra-durability of the zwitterionic DURA-Z coating.  
The DURA-Z coating can be easily applied to a variety of substrates including 
stainless steel, wood, and glass (Fig. 5-8(a)) by combining the use of DURA-Z tape 
and superglue. It should be noted that the glass substrate was pre-treated with a 
thin layer of EVO-Stik glue before applying the coating due to the low affinity 




substrates were also found to be durable as indicated by unchanged great 
anti-fouling property even after two months of incubation in water (Figure 5-9). They 
were also tested for E. coli biofilm resistance for 30 days using dynamic bacterial 
challenge condition. Almost zero bacteria adhesion was achieved on all tested 
DURA-Z coatings despite different types of substrates were coated (Figure 5-10).  
Practically speaking, it is frequently desirable that a coating layer can be fully 
removed from the substrate, followed by a new coating to be re-applied 
seamlessly189.  However, reapplication of coating was hard to realize based on the 
chemical modification methods190-192 without significantly damaging the original 
substrates. Here the DRUA-Z coating binds with the substrate surface through 
commercial superglues which are dissolvable in organic solvents. Take DURA-Z 
coated stainless steel for example (Figure 5-8(b)), upon 1-hour incubation in acetone, 
the coating came off spontaneously without any damage to the substrate surface. It 
is feasible to re-apply a new DURA-Z coating on this same stainless steel substrate, 
and the new coating resisted protein binding as efficient as when it was first applied 
(Figure 5-8(c)). 
The key for the DURA-Z coating to achieve the ultra-durability is because of the 
use of superglue to strongly bind the super-hydrophilic polymer network (PCBAA 
hydrogel) and a hydrophobic substrate together. This is against common sense since 
commercial superglue is known to only bind hydrophobic substrates. Superglues are 
based on the rapid solidification of hydrophobic cyanoacrylate polymers, which have 




to glue linear zwitterionic PCBAA polymer powder and highly concentrated 
PCBAA/water solution on substrates using superglue, but the attached polymers 
quickly dissolved upon incubation in water and both obtained surfaces showed 
hydrophobic nature (Figure 5-11). The success of using superglue to strongly bind 
hydrophilic zwitterionic hydrogel layer (DURA-Z coating) is attributed to the unique 
inter-penetration structure formed between these two (Figure 5-2(a) and (d)). It is 
expected that during the curing process, liquid cyanoacrylate monomers penetrated 
into the zwitterionic hydrogel network and were crosslinked. The entanglement 
between the DURA-Z and superglue networks immobilized the coating on the 
substrate for as long and strong as the superglue adhesive can last.  
For biofilm resistance performance, DURA-Z coating is unprecedented. 
State-of-the-art anti-fouling coatings started to accumulate bacteria after just a few 
hours of contact and would be covered with dense biofilm usually within ~7 days. 
DURA-Z coating was able to achieve almost “zero” bacteria adhesion even after 
one-month continuous contact with high concentration bacteria. This coating 
technology is convenient to apply and can promisingly solve the biofilm threat, 
which deteriorates public health and impedes the function of most biomedical 
devices.    
In summary, we developed an ultra-durable and robust zwitterionic polymer 
network coating, namely DURA-Z, by combining the use of commercial superglue 
and the developed DURA-Z tapes. DURA-Z coating showed great stability and 




mechanical damage tests. With superior anti-fouling and durable property, the 
coating was able to achieve almost zero adhesion of bacteria after one-month 
continuous co-culture with E. coli bacteria at extremely high density. DURA-Z coating 
is applicable to various common substrates to achieve long term durability and 
anti-fouling performance, and when needed, it can be easily removed and re-applied. 
This simple and inexpensive method will find applications as anti-fouling coatings in 














Figure 5-1 (a) structure of DURA-Z tape, (b) DURA-Z tape under pulling, bending 






Figure 5-2 (a) SEM imaging on the surface and sectioning of uncoated PU, superglue 
and DURA-Z coated substrates (scale bar = 100 μm), (b) water contact angles on bare 
PU, superglue and DURA-Z coated substrates, (c) IR spectra of bare PU surface, 
superglue coated PU surface, DURA-Z coated surface and zwitterionic PCBAA 






Figure 5-3 AFM images of bare PU substrate, superglue and DURA-Z coated PU 






Figure 5-4 Antifouling property of DURA-Z coating after durability tests. (a) 3-month 
incubation in water and (b) 50 days exposure to PBS shearing at room temperature. 
Data were showed as mean of replicates (n=3) ± standard deviation. Statistical 
analysis: unpaired, two-tailed t-test, n.s.: no significant difference at P > 0.05, 







Figure 5-5 Antifouling property of DURA-Z coating after various durability and 
mechanical damage tests. (a) 30 days exposure to PBS shearing under body 
temperature, (b) 30 days exposure to perpendicular water flush, (c) 20 cycles of 
abrasion test under 570 kPa, and (d) random scratch by a scalpel. The antifouling 
property was evaluated by the resistance of human fibrinogen binding on the 
surface (absorbed protein) before and after the coating being challenged. All data 
were showed as mean of replicates (n=3) ± standard deviation. Statistical analysis: 
unpaired, two-tailed t-test, n.s.: no significant difference at P > 0.05, meaning the 





Figure 5-6 representative SEM images of bacteria adhesion on bare PU, superglue 
and DURA-Z coated PU substrates after 30 days of co-culture with E. coli bacteria at 
(a) shaking condition and (b) static condition. Attached bacterial density was 
calculated for (c) shaking condition and (d) static condition. ***: All data are 
presented as mean of biological replicates (n=6) ± standard deviation. Statistical 
analysis: one-way ANOVA with Bonferroni multi-comparison. ***: p < 0.0001. Scale 






Figure 5-7 representative SEM images showing bacteria adhesion on DURA-Z coating 
after 30 days of culture with bacteria at static condition without any rinsing. Scale 








Figure 5-8 (a) DURA-Z coating on wood, stainless steel, and glass substrates. (b) Easy 
removal and re-application of DURA-Z coating on stainless steel substrate, and (c) 
corresponding antifouling property. All data were showed as mean of replicates 
(n=3) ± standard deviation. Statistical analysis: unpaired, two-tailed t-test, n.s.: no 







Figure 5-9 Antifouling property of DURA-Z coating on wood, stainless steel and glass 
substrates after two-month incubation in water. All data were showed as mean of 
replicates (n=3) ± standard deviation. Statistical analysis: unpaired, two-tailed t-test, 

























Figure 5-10 (a) representative SEM images of bacteria adhesion on wood, stainless 
steel, glass and DURA-Z coating on these substrates after 30 days of co-culture with 
bacteria at shaking condition, and (b) calculated bacterial density on wood, stainless 
steel, glass and DURA-Z coatings on these substrates. All data are presented as mean 
of biological replicates (n=6) ± standard deviation. Statistical analysis: unpaired 







Figure 5-11 (a) PCBAA polymer powder and (b) PCBAA water solution were glued on 
PU substrates. The coated surface showed hydrophobic nature after incubation in 




CHAPTER 6. CONCLUSION AND OUTLOOK 
The focus of this thesis is to study the potentials of the zwitterionic PCB materials 
in solving several key challenges in various applications as stabilizing materials for 
nanoparticles, hydrogels, and surface coatings, respectively. Specifically, this thesis 
involves the work of a one-step synthesis of zwitterionic polymer modified carbon 
nanoparticles, pancreatic islets encapsulation by PCB hydrogel materials and 
subsequent transplantation to achieve long-term diabetic reversal effect, and a 
durable zwitterionic PCB polymer coating for various substrates to resist long-term 
biofilm formation. These subjects are introduced separately in the following 
paragraphs. 
The study on the ultra-stable carbon nanoparticles was a novel strategy to 
fabricate core-shell NPs with superior stability directly and solely from anti-fouling 
zwitterionic polymers through single step of microwave heating. We found that Only 
those zwitterionic polymers that are stable through high temperature microwave 
heating can produce zwitterionic polymer shell-carbon core NPs, which can be 
further purified through sucrose gradient centrifugation. The resulting nanoparticle 
showed superior colloid stability in bio-relevant media and even the freeze-drying 
conditions. We expect this green chemistry in making ultra-stable NPs can inspire 
future functional NPs to be developed. These ultra-stable florescent carbon 
nanoparticles will find applications in cell labelling and trackable drug delivery 
systems.  




ever known promoting functional neovascularization as good as natural body system. 
A zwitterionic carboxy betaine containing hydrogel was found to promote 
vascularization at the subcutaneous (s.c.) site to the same density level as normal 
tissue, and to maintain that high-level vasculature for at least 6 months. The newly 
formed blood vessels were perfused and they approached the implanted zwitterionic 
gel surface as close as below 20 micrometers away. Consequently, the zwitterionic 
hydrogel was highly accessible by circulating blood, even after 5 months of 
implantation. This finding was highlighted by using zwitterionic hydrogel in 
encapsulating islets for the treatment Type 1 diabetes. The zwitterionic hydrogel 
based novel system remarkably outperforms the state-of-the-art technology using 
alginate encapsulating materials at highly challenging s.c. site. We expect, with 
natural tissue-like blood accessibility, the zwitterionic hydrogel is a promising 
platform to improve the long-term performance of most current implantable devices 
to fight against various diseases.  
For the study on tough and durable zwitterionic polymer coating to resist 
micro-organism biofilm, we first developed a novel zwitterionic macro-crosslinker to 
overcome the vulnerability of zwitterionic coating on common hydrophobic 
polyrethane substrate. Coating formed using the macro-crosslinker exhibited much 
greater thickness and durability compared to common polymer brush coating and 
brush coating crosslinked with small-molecule crosslinkers. Upon incubation in water, 
macro-crosslinker coating was able to sustain hydrophilicity for more than two weeks. 




anti-fouling property to resist protein and bacteria adsorption after one week 
treatment. The durable zwitterionic macro-crosslinker coating can be potentially 
applied to resist micro-organism adhesion on blood-contact biomedical devices or for 
marine coating applications. 
For the anti-biofilm purpose, the durability of the macro-crosslinker coating was 
not enough. We then the developed a DURA-Z coating to further increase the 
durability and toughness of zwitterionic coating that was able to resist long term 
biofilm resistance. The DURA-Z coating can be easily and universally applied on 
common substrates. Against conventional wisdom, commercial superglue only for 
binding hydrophobic materials was used to strongly immobilize the super-hydrophilic 
DURA-Z coating through interpenetration. The fabricated DURA-Z coating retained 
anti-fouling property after 90 days of immersion in water, 50 days of buffer shearing 
and 30 days of water-flushing, and after repeated knife-scratch and sandpaper 
abrasion under 570 kPa. The DURA-Z coating achieved a rarely reported long-term 
biofilm resistance: it remained almost "zero" bacteria adhesion after continuously 
challenged by more than 109 bacterial cells per ml culture medium for 30 days. The 
DURA-Z coating greatly extended the industrial application of zwitterionic polymer 
coating by overcoming the durability and toughness challenges, and can be applied in 
medical devices and marine coating to protect working surfaces from biofilm growth 
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Based on the superior anti-fouling property, the zwitterionic materials had great 
potential in applications such as medical implants, medical device coating, and 
marine coating industry. This dissertation will focus on the applications of 
zwitterionic materials in stabilizing carbon nanoparticles, as implantable devices and 
durable coating on medical devices for long-term anti-microbial purposes. Chapter 2 
of the thesis will discuss a simple method to synthesis carbon nanoparticles stabilized 
by zwitterionic polymers. Chapter 3 of the thesis reports the use of zwitterionic 
hydrogel to encapsulate islet of Langerhans to treat Type 1 diabetes. In Chapter 4 and 
5, several methods were developed to improve the stability and durability of 
zwitterionic anti-fouling coating. The improved coatings were able to address the 
notorious biofilm issue on medical devices by resisting the bacteria adhesion for a 
long term in highly concentrated bacteria culture media. These works greatly extend 
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